10976058	Estrogens	Dupont S	Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes.	Development	2000	257
11306549	Estrogens	Vooijs M	A highly efficient ligand-regulated Cre recombinase mouse line shows that LoxP recombination is position dependent.	EMBO reports	2001	116
12075357	Estrogens	Urano T	Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth.	Nature	2002	86
12756295	Estrogens	Yadav N	Specific protein methylation defects and gene expression perturbations in coactivator-associated arginine methyltransferase 1-deficient mice.	Proceedings of the National Academy of Sciences of the United States of America	2003	96
14578209	Estrogens	Lin EY	Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases.	The American journal of pathology	2003	356
14996752	Estrogens	Kuang SQ	AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice.	Cancer research	2004	73
15001666	Estrogens	Bourdeau V	Genome-wide identification of high-affinity estrogen response elements in human and mouse.	Molecular endocrinology	2004	102
15380517	Estrogens	Torres-Arzayus MI	High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene.	Cancer cell	2004	148
15617686	Estrogens	Clarke RB	A putative human breast stem cell population is enriched for steroid receptor-positive cells.	Developmental biology	2005	89
16803960	Estrogens	Musatov S	RNAi-mediated silencing of estrogen receptor {alpha} in the ventromedial nucleus of hypothalamus abolishes female sexual behaviors.	Proceedings of the National Academy of Sciences of the United States of America	2006	69
16849684	Estrogens	Asselin-Labat ML	Steroid hormone receptor status of mouse mammary stem cells.	Journal of the National Cancer Institute	2006	98
16885386	Estrogens	Wolf I	15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer.	Cancer research	2006	63
17046690	Estrogens	Wintermantel TM	Definition of estrogen receptor pathway critical for estrogen positive feedback to gonadotropin-releasing hormone neurons and fertility.	Neuron	2006	189
17190790	Estrogens	Sleeman KE	Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland.	The Journal of cell biology	2007	122
17332335	Estrogens	Gupta PB	Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers.	Cancer research	2007	60
17369357	Estrogens	Ciarloni L	Amphiregulin is an essential mediator of estrogen receptor alpha function in mammary gland development.	Proceedings of the National Academy of Sciences of the United States of America	2007	98
17456738	Estrogens	Hameyer D	Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues.	Physiological genomics	2007	67
17493263	Estrogens	Herschkowitz JI	Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.	Genome biology	2007	443
17626182	Estrogens	Liu X	Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	115
17785410	Estrogens	Feng Y	Estrogen receptor-alpha expression in the mammary epithelium is required for ductal and alveolar morphogenesis in mice.	Proceedings of the National Academy of Sciences of the United States of America	2007	77
18375767	Estrogens	Tan-Wong SM	Dynamic interactions between the promoter and terminator regions of the mammalian BRCA1 gene.	Proceedings of the National Academy of Sciences of the United States of America	2008	62
18957414	Estrogens	Zhang X	Esrrb activates Oct4 transcription and sustains self-renewal and pluripotency in embryonic stem cells.	The Journal of biological chemistry	2008	60
19109434	Estrogens	Wang S	Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation.	Proceedings of the National Academy of Sciences of the United States of America	2009	50
19602591	Estrogens	Hartman J	Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells.	Cancer research	2009	52
19838210	Estrogens	Hao L	Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells.	Oncogene	2010	43
20484027	Estrogens	Meyer MJ	CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer.	Cancer research	2010	57
20484414	Estrogens	Wilson BJ	An acetylation switch modulates the transcriptional activity of estrogen-related receptor alpha.	Molecular endocrinology	2010	52
20679727	Estrogens	Jiang Z	Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status.	The Journal of clinical investigation	2010	58
20739412	Estrogens	Brisken C	Hormone action in the mammary gland.	Cold Spring Harbor perspectives in biology	2010	107
20813035	Estrogens	Prat A	Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.	Breast cancer research 	2010	582
21057539	Estrogens	Patel JB	Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22.	Oncogene	2011	39
21149639	Estrogens	Sandén C	G protein-coupled estrogen receptor 1/G protein-coupled receptor 30 localizes in the plasma membrane and traffics intracellularly on cytokeratin intermediate filaments.	Molecular pharmacology	2011	41
21369698	Estrogens	Catchpole S	PLU-1/JARID1B/KDM5B is required for embryonic survival and contributes to cell proliferation in the mammary gland and in ER+ breast cancer cells.	International journal of oncology	2011	45
21482677	Estrogens	Meyer DS	Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.	Cancer research	2011	43
21553120	Estrogens	Guttilla IK	Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs.	Breast cancer research and treatment	2012	38
21775990	Estrogens	Matson CK	DMRT1 prevents female reprogramming in the postnatal mammalian testis.	Nature	2011	92
22158945	Estrogens	Nasser MW	S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways.	Cancer research	2012	38
22264274	Estrogens	Chan SR	STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas.	Breast cancer research 	2012	56
22411819	Estrogens	Xu X	Evidence for type II cells as cells of origin of K-Ras-induced distal lung adenocarcinoma.	Proceedings of the National Academy of Sciences of the United States of America	2012	65
22495674	Estrogens	Filardo EJ	Minireview: G protein-coupled estrogen receptor-1, GPER-1: its mechanism of action and role in female reproductive cancer, renal and vascular physiology.	Endocrinology	2012	73
22496457	Estrogens	Palafox M	RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.	Cancer research	2012	44
22632819	Estrogens	Zhi X	YAP promotes breast cell proliferation and survival partially through stabilizing the KLF5 transcription factor.	The American journal of pathology	2012	33
22821401	Estrogens	Kabos P	Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.	Breast cancer research and treatment	2012	40
22993197	Estrogens	Motiani RK	Orai3 is an estrogen receptor α-regulated Ca²⁺ channel that promotes tumorigenesis.	FASEB journal 	2013	45
23047698	Estrogens	Song H	Functional characterization of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesis.	Proceedings of the National Academy of Sciences of the United States of America	2012	55
23088371	Estrogens	Shehata M	Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland.	Breast cancer research 	2012	88
23442322	Estrogens	Ithimakin S	HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.	Cancer research	2013	62
23621987	Estrogens	Meier-Abt F	Parity induces differentiation and reduces Wnt/Notch signaling ratio and proliferation potential of basal stem/progenitor cells isolated from mouse mammary epithelium.	Breast cancer research 	2013	35
24469049	Estrogens	Cyr AR	TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis.	Oncogene	2015	22
24567396	Estrogens	Gorrini C	Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway.	Proceedings of the National Academy of Sciences of the United States of America	2014	20
24844244	Estrogens	Wang Y	MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells.	eLife	2014	27
25013076	Estrogens	Yu M	Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility.	Science	2014	167
25017071	Estrogens	Nagarajan S	Bromodomain protein BRD4 is required for estrogen receptor-dependent enhancer activation and gene transcription.	Cell reports	2014	41
25168343	Estrogens	Santen RJ	Estrogen metabolites and breast cancer.	Steroids	2015	25
25538079	Estrogens	Martz CA	Systematic identification of signaling pathways with potential to confer anticancer drug resistance.	Science signaling	2014	47
25609169	Estrogens	Zhao Y	Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis.	Science translational medicine	2015	18
26189910	Estrogens	Prossnitz ER	What have we learned about GPER function in physiology and disease from knockout mice?	The Journal of steroid biochemistry and molecular biology	2015	19
26286584	Estrogens	Strong AL	Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers.	Breast cancer research 	2015	20
26459763	Estrogens	Gernapudi R	MicroRNA 140 Promotes Expression of Long Noncoding RNA NEAT1 in Adipogenesis.	Molecular and cellular biology	2016	16
26599602	Estrogens	Tam A	Sex Differences in Airway Remodeling in a Mouse Model of Chronic Obstructive Pulmonary Disease.	American journal of respiratory and critical care medicine	2016	15
27214280	Estrogens	Torrano V	The metabolic co-regulator PGC1α suppresses prostate cancer metastasis.	Nature cell biology	2016	26
27775705	Estrogens	Horiuchi D	PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.	Nature medicine	2016	12
28154167	Estrogens	Ohoka N	In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs).	The Journal of biological chemistry	2017	8
28186560	Estrogens	Riar AK	Sex specific activation of the ERα axis of the mitochondrial UPR (UPRmt) in the G93A-SOD1 mouse model of familial ALS.	Human molecular genetics	2017	6
2993906	Peptides	Cuttitta F	Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer.	Nature	1985	169
10860979	Peptides	Wang JL	Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells.	Proceedings of the National Academy of Sciences of the United States of America	2000	142
11084031	Peptides	Futaki S	Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery.	The Journal of biological chemistry	2001	209
12118245	Peptides	Fulda S	Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.	Nature medicine	2002	133
12509463	Peptides	Weng AP	Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling.	Molecular and cellular biology	2003	145
14871849	Peptides	Blank C	PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.	Cancer research	2004	171
15355971	Peptides	Williams TM	Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion.	The Journal of biological chemistry	2004	89
15380518	Peptides	Arap MA	Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands.	Cancer cell	2004	116
15647826	Peptides	Sun YX	Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo.	Journal of bone and mineral research 	2005	105
15958392	Peptides	Ishihama Y	Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein.	Molecular & cellular proteomics 	2005	513
16061848	Peptides	Arumugam T	S100P promotes pancreatic cancer growth, survival, and invasion.	Clinical cancer research 	2005	65
17205123	Peptides	Gelain F	Designer self-assembling peptide nanofiber scaffolds for adult mouse neural stem cell 3-dimensional cultures.	PloS one	2006	77
18071913	Peptides	Kim SY	Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases.	Clinical & experimental metastasis	2008	54
18416599	Peptides	Kelly KA	Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma.	PLoS medicine	2008	75
18829396	Peptides	Karmali PP	Targeting of albumin-embedded paclitaxel nanoparticles to tumors.	Nanomedicine 	2009	58
19255147	Peptides	Beauvais DM	Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor.	The Journal of experimental medicine	2009	81
19255442	Peptides	Belkina NV	LOK is a major ERM kinase in resting lymphocytes and regulates cytoskeletal rearrangement through ERM phosphorylation.	Proceedings of the National Academy of Sciences of the United States of America	2009	47
19907488	Peptides	Moellering RE	Direct inhibition of the NOTCH transcription factor complex.	Nature	2009	232
20194714	Peptides	Pilon-Thomas S	Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.	Journal of immunology	2010	54
20544025	Peptides	Jin G	An antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis.	PloS one	2010	43
20703838	Peptides	Kim YS	Intestinal goblet cells and mucins in health and disease: recent insights and progress.	Current gastroenterology reports	2010	164
21460061	Peptides	Brosch M	Shotgun proteomics aids discovery of novel protein-coding genes, alternative splicing, and "resurrected" pseudogenes in the mouse genome.	Genome research	2011	40
21857646	Peptides	Schraivogel D	CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells.	The EMBO journal	2011	48
22622039	Peptides	LaBelle JL	A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers.	The Journal of clinical investigation	2012	62
23297075	Peptides	Wu Z	Development and evaluation of 18F-TTCO-Cys40-Exendin-4: a PET probe for imaging transplanted islets.	Journal of nuclear medicine 	2013	32
23533277	Peptides	Kamaly N	Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles.	Proceedings of the National Academy of Sciences of the United States of America	2013	43
23714121	Peptides	Shi P	Elastin-based protein polymer nanoparticles carrying drug at both corona and core suppress tumor growth in vivo.	Journal of controlled release 	2013	26
24855945	Peptides	Birnbaum ME	Deconstructing the peptide-MHC specificity of T cell recognition.	Cell	2014	86
25818419	Peptides	Jiang L	Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response.	Biomaterials	2015	20
27524110	Peptides	Ratsimandresy RA	The AIM2 inflammasome is a central regulator of intestinal homeostasis through the IL-18/IL-22/STAT3 pathway.	Cellular & molecular immunology	2017	15
28024296	Peptides	Matsumoto A	mTORC1 and muscle regeneration are regulated by the LINC00961-encoded SPAR polypeptide.	Nature	2017	26
1904009	Zinc	Haupt Y	Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice.	Cell	1991	141
7682653	Zinc	Miller IJ	A novel, erythroid cell-specific murine transcription factor that binds to the CACCC element and is related to the Krüppel family of nuclear proteins.	Molecular and cellular biology	1993	216
8649389	Zinc	Filippova GN	An exceptionally conserved transcriptional repressor, CTCF, employs different combinations of zinc fingers to bind diverged promoter sequences of avian and mammalian c-myc oncogenes.	Molecular and cellular biology	1996	188
9032291	Zinc	Weiss MJ	Erythroid-cell-specific properties of transcription factor GATA-1 revealed by phenotypic rescue of a gene-targeted cell line.	Molecular and cellular biology	1997	144
9482838	Zinc	Blobel GA	CREB-binding protein cooperates with transcription factor GATA-1 and is required for erythroid differentiation.	Proceedings of the National Academy of Sciences of the United States of America	1998	113
9553047	Zinc	Tsang AP	Failure of megakaryopoiesis and arrested erythropoiesis in mice lacking the GATA-1 transcriptional cofactor FOG.	Genes & development	1998	106
10725363	Zinc	Nilsson M	Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1.	Proceedings of the National Academy of Sciences of the United States of America	2000	99
11792318	Zinc	Nakashima K	The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation.	Cell	2002	723
12798299	Zinc	Moss EG	Conservation of the heterochronic regulator Lin-28, its developmental expression and microRNA complementary sites.	Developmental biology	2003	102
15729333	Zinc	He X	The zinc finger transcription factor Th-POK regulates CD4 versus CD8 T-cell lineage commitment.	Nature	2005	134
15825076	Zinc	Katz JP	Loss of Klf4 in mice causes altered proliferation and differentiation and precancerous changes in the adult stomach.	Gastroenterology	2005	98
16763212	Zinc	Ma Y	SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice.	Blood	2006	73
17671182	Zinc	Ghaleb AM	Haploinsufficiency of Krüppel-like factor 4 promotes adenomatous polyposis coli dependent intestinal tumorigenesis.	Cancer research	2007	60
17719541	Zinc	Das S	Hzf Determines cell survival upon genotoxic stress by modulating p53 transactivation.	Cell	2007	68
18003899	Zinc	Li M	Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression.	Proceedings of the National Academy of Sciences of the United States of America	2007	71
18054006	Zinc	Nandan MO	Krüppel-like factor 5 mediates cellular transformation during oncogenic KRAS-induced intestinal tumorigenesis.	Gastroenterology	2008	57
18192284	Zinc	Liu Y	Zeb1 links epithelial-mesenchymal transition and cellular senescence.	Development	2008	89
18587387	Zinc	Perez EE	Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases.	Nature biotechnology	2008	358
19060217	Zinc	Yang J	Genome-wide analysis reveals Sall4 to be a major regulator of pluripotency in murine-embryonic stem cells.	Proceedings of the National Academy of Sciences of the United States of America	2008	59
19701203	Zinc	Han YG	Dual and opposing roles of primary cilia in medulloblastoma development.	Nature medicine	2009	134
19935649	Zinc	Wellner U	The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs.	Nature cell biology	2009	521
20200519	Zinc	Gupta RK	Transcriptional control of preadipocyte determination by Zfp423.	Nature	2010	155
21102519	Zinc	Roy LD	MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition.	Oncogene	2011	89
21655080	Zinc	Simsek D	DNA ligase III promotes alternative nonhomologous end-joining during chromosomal translocation formation.	PLoS genetics	2011	97
21890822	Zinc	Ohashi S	A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT-competent cells that express the ZEB transcription factors.	Cancer research	2011	47
22561374	Zinc	Stolzenburg S	Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer.	Nucleic acids research	2012	54
22624712	Zinc	Yu X	Allele-specific p53 mutant reactivation.	Cancer cell	2012	81
22751931	Zinc	Morita M	A novel 4EHP-GIGYF2 translational repressor complex is essential for mammalian development.	Molecular and cellular biology	2012	33
22937066	Zinc	Lin ZS	Krüppel-like factor 4, a tumor suppressor in hepatocellular carcinoma cells reverts epithelial mesenchymal transition by suppressing slug expression.	PloS one	2012	39
24013668	Zinc	Schjerven H	Selective regulation of lymphopoiesis and leukemogenesis by individual zinc fingers of Ikaros.	Nature immunology	2013	32
24518294	Zinc	Truong HH	β1 integrin inhibition elicits a prometastatic switch through the TGFβ-miR-200-ZEB network in E-cadherin-positive triple-negative breast cancer.	Science signaling	2014	23
24550295	Zinc	Zhao J	Polyclonal type II natural killer T cells require PLZF and SAP for their development and contribute to CpG-mediated antitumor response.	Proceedings of the National Academy of Sciences of the United States of America	2014	26
24626089	Zinc	Nakaya T	KLF5 regulates the integrity and oncogenicity of intestinal stem cells.	Cancer research	2014	24
24769727	Zinc	Denecker G	Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression.	Cell death and differentiation	2014	27
24952462	Zinc	Whissell G	The transcription factor GATA6 enables self-renewal of colon adenoma stem cells by repressing BMP gene expression.	Nature cell biology	2014	25
25404366	Zinc	Prevot N	Mammalian target of rapamycin complex 2 regulates invariant NKT cell development and function independent of promyelocytic leukemia zinc-finger.	Journal of immunology	2015	20
25531323	Zinc	Weber CE	Osteopontin mediates an MZF1-TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer.	Oncogene	2015	30
25739959	Zinc	Memmi EM	p63 Sustains self-renewal of mammary cancer stem cells through regulation of Sonic Hedgehog signaling.	Proceedings of the National Academy of Sciences of the United States of America	2015	43
26023187	Zinc	Koo BK	Porcupine inhibitor suppresses paracrine Wnt-driven growth of Rnf43;Znrf3-mutant neoplasia.	Proceedings of the National Academy of Sciences of the United States of America	2015	16
26236991	Zinc	Lovisa S	Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis.	Nature medicine	2015	75
26582948	Zinc	Clark HL	Zinc and Manganese Chelation by Neutrophil S100A8/A9 (Calprotectin) Limits Extracellular Aspergillus fumigatus Hyphal Growth and Corneal Infection.	Journal of immunology	2016	20
26649818	Zinc	Wertz IE	Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation.	Nature	2015	33
27294509	Zinc	Wu LM	Zeb2 recruits HDAC-NuRD to inhibit Notch and controls Schwann cell differentiation and remyelination.	Nature neuroscience	2016	18
28092692	Zinc	Isakova A	SMiLE-seq identifies binding motifs of single and dimeric transcription factors.	Nature methods	2017	10
7585012	Bromodeoxyuridine	Holmgren L	Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression.	Nature medicine	1995	246
11739500	Bromodeoxyuridine	Allman D	Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation.	Journal of immunology	2001	179
11969254	Bromodeoxyuridine	Welm BE	Sca-1(pos) cells in the mouse mammary gland represent an enriched progenitor cell population.	Developmental biology	2002	152
14734483	Bromodeoxyuridine	Tang XH	Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice.	Clinical cancer research 	2004	85
15825074	Bromodeoxyuridine	Bachem MG	Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells.	Gastroenterology	2005	149
16140584	Bromodeoxyuridine	Zhao Y	High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation.	Molecular therapy 	2006	76
16140970	Bromodeoxyuridine	Zhou HJ	SRC-3 is required for prostate cancer cell proliferation and survival.	Cancer research	2005	82
16314438	Bromodeoxyuridine	Shapiro-Shelef M	Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow.	The Journal of experimental medicine	2005	69
18375791	Bromodeoxyuridine	Sawanobori Y	Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice.	Blood	2008	105
18458345	Bromodeoxyuridine	Zhang C	Inhibition of Wnt signaling by the osteoblast-specific transcription factor Osterix.	Proceedings of the National Academy of Sciences of the United States of America	2008	54
19062086	Bromodeoxyuridine	Wilson A	Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair.	Cell	2008	493
19072981	Bromodeoxyuridine	Chu P	Characterization of a subpopulation of colon cancer cells with stem cell-like properties.	International journal of cancer	2009	51
19342421	Bromodeoxyuridine	Takakura A	Renal injury is a third hit promoting rapid development of adult polycystic kidney disease.	Human molecular genetics	2009	63
19676123	Bromodeoxyuridine	May R	Doublecortin and CaM kinase-like-1 and leucine-rich-repeat-containing G-protein-coupled receptor mark quiescent and cycling intestinal stem cells, respectively.	Stem cells	2009	61
20028388	Bromodeoxyuridine	Ishimoto T	CD44+ slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis.	Cancer science	2010	41
21343390	Bromodeoxyuridine	Chang Q	Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer.	Cancer research	2011	58
23243025	Bromodeoxyuridine	Belarbi K	CCR2 deficiency prevents neuronal dysfunction and cognitive impairments induced by cranial irradiation.	Cancer research	2013	26
23379788	Bromodeoxyuridine	Jiang R	IL-22 is related to development of human colon cancer by activation of STAT3.	BMC cancer	2013	28
24284627	Bromodeoxyuridine	Li Q	Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness.	Nature	2013	32
24586944	Bromodeoxyuridine	Di Martino MT	In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells.	PloS one	2014	24
24884509	Bromodeoxyuridine	Tu K	Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma.	Molecular cancer	2014	30
25028469	Bromodeoxyuridine	Zhang YX	Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo.	Molecular cancer therapeutics	2014	29
26908603	Bromodeoxyuridine	Toonen JA	NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.	Human molecular genetics	2016	13
9887098	Hyaluronic Acid	Yu Q	Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion.	Genes & development	1999	145
11731267	Hyaluronic Acid	Csoka AB	The six hyaluronidase-like genes in the human and mouse genomes.	Matrix biology 	2001	112
12145277	Hyaluronic Acid	Ghatak S	Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway.	The Journal of biological chemistry	2002	83
19218337	Hyaluronic Acid	Bharadwaj AG	Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing.	The American journal of pathology	2009	52
19783037	Hyaluronic Acid	Choi KY	Self-assembled hyaluronic acid nanoparticles for active tumor targeting.	Biomaterials	2010	55
19965872	Hyaluronic Acid	Takahashi E	Tumor necrosis factor-alpha regulates transforming growth factor-beta-dependent epithelial-mesenchymal transition by promoting hyaluronan-CD44-moesin interaction.	The Journal of biological chemistry	2010	58
20197461	Hyaluronic Acid	Xu Y	CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma.	Cancer research	2010	59
20823158	Hyaluronic Acid	Kobayashi N	Hyaluronan deficiency in tumor stroma impairs macrophage trafficking and tumor neovascularization.	Cancer research	2010	43
21387290	Hyaluronic Acid	Urakawa H	Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo.	International journal of cancer	2012	35
21673348	Hyaluronic Acid	Ellis SL	The relationship between bone, hemopoietic stem cells, and vasculature.	Blood	2011	42
23633482	Hyaluronic Acid	Hiraga T	Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production.	Cancer research	2013	69
23783513	Hyaluronic Acid	Tian X	High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat.	Nature	2013	130
3489291	Cyclophosphamide	Rosenberg SA	A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.	Science	1986	209
11325840	Cyclophosphamide	Machiels JP	Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.	Cancer research	2001	130
12015983	Cyclophosphamide	Schmitt CA	A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy.	Cell	2002	257
12531874	Cyclophosphamide	Lévesque JP	Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide.	The Journal of clinical investigation	2003	164
15381730	Cyclophosphamide	Turk MJ	Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.	The Journal of experimental medicine	2004	167
15689397	Cyclophosphamide	Gorbacheva VY	Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex.	Proceedings of the National Academy of Sciences of the United States of America	2005	67
15883172	Cyclophosphamide	Ercolini AM	Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response.	The Journal of experimental medicine	2005	143
16304055	Cyclophosphamide	Alpdogan O	Keratinocyte growth factor (KGF) is required for postnatal thymic regeneration.	Blood	2006	64
17066459	Cyclophosphamide	Houghton PJ	The pediatric preclinical testing program: description of models and early testing results.	Pediatric blood & cancer	2007	188
17234791	Cyclophosphamide	Hou DY	Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.	Cancer research	2007	146
17255288	Cyclophosphamide	Bracci L	Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.	Clinical cancer research 	2007	66
17404107	Cyclophosphamide	Mohammad RM	Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.	Clinical cancer research 	2007	60
18281474	Cyclophosphamide	Furuta E	Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1.	Cancer research	2008	91
18378900	Cyclophosphamide	Raffaghello L	Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy.	Proceedings of the National Academy of Sciences of the United States of America	2008	105
19435909	Cyclophosphamide	Wada S	Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model.	Cancer research	2009	49
20145127	Cyclophosphamide	Lee C	Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index.	Cancer research	2010	63
20631380	Cyclophosphamide	Campbell KJ	Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance.	Blood	2010	44
21512138	Cyclophosphamide	Ling S	An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancer.	Cancer research	2011	37
22072556	Cyclophosphamide	Srinivasan M	Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans.	Blood	2012	66
24607504	Cyclophosphamide	Keenan BP	A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.	Gastroenterology	2014	28
25139358	Cyclophosphamide	Ganguly S	Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.	Blood	2014	24
25415283	Cyclophosphamide	Soares KC	PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.	Journal of immunotherapy	2015	66
7973635	Doxorubicin	Lowe SW	p53 status and the efficacy of cancer therapy in vivo.	Science	1994	225
9506948	Doxorubicin	Yeh WC	FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis.	Science	1998	185
9661897	Doxorubicin	Baselga J	Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.	Cancer research	1998	130
15756033	Doxorubicin	Cohen BD	Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.	Clinical cancer research 	2005	86
15763623	Doxorubicin	Lee ES	Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor.	Journal of controlled release 	2005	95
16079837	Doxorubicin	Braig M	Oncogene-induced senescence as an initial barrier in lymphoma development.	Nature	2005	348
16361566	Doxorubicin	Primeau AJ	The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors.	Clinical cancer research 	2005	101
17415413	Doxorubicin	Biswas S	Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.	The Journal of clinical investigation	2007	100
17823410	Doxorubicin	Corney DC	MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth.	Cancer research	2007	223
17875987	Doxorubicin	Tazawa H	Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2007	294
18037988	Doxorubicin	Suliman HB	The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy.	The Journal of clinical investigation	2007	89
18574145	Doxorubicin	Burgess DJ	Topoisomerase levels determine chemotherapy response in vitro and in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2008	87
18818206	Doxorubicin	Nasser MW	Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1.	The Journal of biological chemistry	2008	137
19103993	Doxorubicin	Zhu W	Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway.	Circulation	2009	55
19156211	Doxorubicin	Mahller YY	Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus.	PloS one	2009	52
19433796	Doxorubicin	Lee J	A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4.	Proceedings of the National Academy of Sciences of the United States of America	2009	64
19584283	Doxorubicin	Fornari F	MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.	Cancer research	2009	117
19956757	Doxorubicin	Liao D	Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model.	PloS one	2009	109
20074638	Doxorubicin	Venkatesan B	WNT1-inducible signaling pathway protein-1 activates diverse cell survival pathways and blocks doxorubicin-induced cardiomyocyte death.	Cellular signalling	2010	46
20378772	Doxorubicin	Sugahara KN	Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.	Science	2010	206
20388796	Doxorubicin	Yoo BK	Molecular mechanism of chemoresistance by astrocyte elevated gene-1.	Cancer research	2010	46
20442777	Doxorubicin	Bandyopadhyay A	Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models.	PloS one	2010	50
20460510	Doxorubicin	Adhikari AS	CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance.	Cancer research	2010	80
20668064	Doxorubicin	Zhang X	Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway.	Cancer research	2010	48
20829328	Doxorubicin	Lockman PR	Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.	Clinical cancer research 	2010	135
20884632	Doxorubicin	Zhao Y	Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy.	Cancer research	2010	56
20935265	Doxorubicin	Calcagno AM	Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.	Journal of the National Cancer Institute	2010	76
21573140	Doxorubicin	Zheng GX	A latent pro-survival function for the mir-290-295 cluster in mouse embryonic stem cells.	PLoS genetics	2011	37
21591812	Doxorubicin	Agarwal A	Remote triggered release of doxorubicin in tumors by synergistic application of thermosensitive liposomes and gold nanorods.	ACS nano	2011	38
21646474	Doxorubicin	Mattarollo SR	Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors.	Cancer research	2011	73
21996747	Doxorubicin	Lo PK	CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.	Oncogene	2012	53
22152097	Doxorubicin	Pham PV	Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy.	Journal of translational medicine	2011	36
22281424	Doxorubicin	Xiao Y	Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging.	Biomaterials	2012	42
22308459	Doxorubicin	Meirelles K	Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance.	Proceedings of the National Academy of Sciences of the United States of America	2012	39
22405901	Doxorubicin	Yang FY	Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor effect in glioblastoma multiforme.	Journal of controlled release 	2012	33
22865457	Doxorubicin	You J	Effective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors.	Cancer research	2012	34
22952218	Doxorubicin	Manzoor AA	Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors.	Cancer research	2012	61
23104132	Doxorubicin	Zhang S	Identification of the molecular basis of doxorubicin-induced cardiotoxicity.	Nature medicine	2012	183
23289892	Doxorubicin	Meng H	Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.	ACS nano	2013	68
23582862	Doxorubicin	Xu W	Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer.	Biomaterials	2013	36
23648833	Doxorubicin	Taratula O	Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA.	Journal of controlled release 	2013	35
23776241	Doxorubicin	Loi S	CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2013	61
23932498	Doxorubicin	Cui Y	Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment.	Biomaterials	2013	25
24004438	Doxorubicin	Jang SC	Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors.	ACS nano	2013	62
24197130	Doxorubicin	Alizadeh D	Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer.	Cancer research	2014	62
24345736	Doxorubicin	Tian Y	A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy.	Biomaterials	2014	126
24502925	Doxorubicin	Bergfeld SA	Bone marrow-derived mesenchymal stromal cells promote survival and drug resistance in tumor cells.	Molecular cancer therapeutics	2014	20
24733904	Doxorubicin	Ma X	Essential role for TrpC5-containing extracellular vesicles in breast cancer with chemotherapeutic resistance.	Proceedings of the National Academy of Sciences of the United States of America	2014	22
25079333	Doxorubicin	Tavora B	Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy.	Nature	2014	21
25153718	Doxorubicin	Datta A	SPHK1 regulates proliferation and survival responses in triple-negative breast cancer.	Oncotarget	2014	22
25330770	Doxorubicin	Liu JC	Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.	EMBO molecular medicine	2014	25
25348805	Doxorubicin	Paranjape AN	Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog.	BMC cancer	2014	31
25368020	Doxorubicin	Park EY	Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance.	Cancer research	2014	38
25453970	Doxorubicin	Ruan S	Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles.	Biomaterials	2015	24
25789975	Doxorubicin	Hall JR	Long noncoding RNA lincRNA-p21 is the major mediator of UVB-induced and p53-dependent apoptosis in keratinocytes.	Cell death & disease	2015	16
26552700	Doxorubicin	Picaud S	Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.	Cancer research	2015	36
26787820	Doxorubicin	Blake SJ	Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy.	Cancer discovery	2016	15
27890659	Doxorubicin	Pi F	RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery.	Nanomedicine 	2017	7
3014349	Carcinogens	Quintanilla M	Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis.	Nature	1986	193
10696569	Carcinogens	Liehr JG	Is estradiol a genotoxic mutagenic carcinogen?	Endocrine reviews	2000	97
11544530	Carcinogens	Krimpenfort P	Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice.	Nature	2001	140
11567106	Carcinogens	Girardi M	Regulation of cutaneous malignancy by gammadelta T cells.	Science	2001	216
11694642	Carcinogens	Talalay P	Phytochemicals from cruciferous plants protect against cancer by modulating carcinogen metabolism.	The Journal of nutrition	2001	92
12193649	Carcinogens	Dinkova-Kostova AT	Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants.	Proceedings of the National Academy of Sciences of the United States of America	2002	420
12878730	Carcinogens	Fingerle-Rowson G	The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting.	Proceedings of the National Academy of Sciences of the United States of America	2003	96
14727734	Carcinogens	Klaunig JE	PPARalpha agonist-induced rodent tumors: modes of action and human relevance.	Critical reviews in toxicology	2003	103
15343391	Carcinogens	Chan KS	Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis.	The Journal of clinical investigation	2004	136
16103220	Carcinogens	List K	Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation.	Genes & development	2005	70
16314486	Carcinogens	Stearman RS	Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model.	The American journal of pathology	2005	91
17283139	Carcinogens	Krelin Y	Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors.	Cancer research	2007	73
19029379	Carcinogens	Iguchi-Manaka A	Accelerated tumor growth in mice deficient in DNAM-1 receptor.	The Journal of experimental medicine	2008	52
19139015	Carcinogens	Czerninski R	Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model.	Cancer prevention research	2009	47
19841737	Carcinogens	Davis R	Nicotine promotes tumor growth and metastasis in mouse models of lung cancer.	PloS one	2009	51
20093774	Carcinogens	Lin RK	The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients.	The Journal of clinical investigation	2010	65
20129250	Carcinogens	Takahashi H	Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation.	Cancer cell	2010	134
20924108	Carcinogens	Elyakim E	hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy.	Cancer research	2010	42
21159633	Carcinogens	Wang L	IL-17 enhances tumor development in carcinogen-induced skin cancer.	Cancer research	2010	52
21369766	Carcinogens	Slocum SL	Nrf2: control of sensitivity to carcinogens.	Archives of toxicology	2011	57
21670304	Carcinogens	Schioppa T	B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2011	60
22467081	Carcinogens	Vitale-Cross L	Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions.	Cancer prevention research	2012	36
22532166	Carcinogens	Ho PL	Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer.	Cancer research	2012	34
23209306	Carcinogens	Ricke RM	Bub1 kinase activity drives error correction and mitotic checkpoint control but not tumor suppression.	The Journal of cell biology	2012	34
23273920	Carcinogens	Schwitalla S	Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors.	Cancer cell	2013	60
23695550	Carcinogens	Alitalo AK	VEGF-C and VEGF-D blockade inhibits inflammatory skin carcinogenesis.	Cancer research	2013	26
23771523	Carcinogens	Quinn BJ	Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling.	Cancer prevention research	2013	30
24280935	Carcinogens	Chan IH	Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells.	Mucosal immunology	2014	22
25363767	Carcinogens	Westcott PM	The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.	Nature	2015	58
25901316	Carcinogens	Souza-Fonseca-Guimaraes F	NK cells require IL-28R for optimal in vivo activity.	Proceedings of the National Academy of Sciences of the United States of America	2015	25
26412304	Carcinogens	Pontel LB	Endogenous Formaldehyde Is a Hematopoietic Stem Cell Genotoxin and Metabolic Carcinogen.	Molecular cell	2015	36
9636188	Methylcholanthrene	Kaplan DH	Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.	Proceedings of the National Academy of Sciences of the United States of America	1998	310
11133760	Methylcholanthrene	Street SE	Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis.	Blood	2001	114
11801676	Methylcholanthrene	Cretney E	Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice.	Journal of immunology	2002	124
16129707	Methylcholanthrene	Smyth MJ	NKG2D function protects the host from tumor initiation.	The Journal of experimental medicine	2005	81
16680149	Methylcholanthrene	Uno T	Eradication of established tumors in mice by a combination antibody-based therapy.	Nature medicine	2006	66
17548588	Methylcholanthrene	Swann JB	Type I IFN contributes to NK cell homeostasis, activation, and antitumor function.	Journal of immunology	2007	59
18178624	Methylcholanthrene	Swann JB	Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis.	Proceedings of the National Academy of Sciences of the United States of America	2008	105
20406893	Methylcholanthrene	Lavon I	Gliomas display a microRNA expression profile reminiscent of neural precursor cells.	Neuro-oncology	2010	42
22318521	Methylcholanthrene	Matsushita H	Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.	Nature	2012	260
22669972	Methylcholanthrene	Liu F	NF-κB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression.	The Journal of biological chemistry	2012	36
22927549	Methylcholanthrene	O'Sullivan T	Cancer immunoediting by the innate immune system in the absence of adaptive immunity.	The Journal of experimental medicine	2012	78
11740565	Cytidine	Petersen S	AID is required to initiate Nbs1/gamma-H2AX focus formation and mutations at sites of class switching.	Nature	2001	178
12732658	Cytidine	Okazaki IM	Constitutive expression of AID leads to tumorigenesis.	The Journal of experimental medicine	2003	132
15902260	Cytidine	Youngren KK	The Ter mutation in the dead end gene causes germ cell loss and testicular germ cell tumours.	Nature	2005	88
17452520	Cytidine	Crouch EE	Regulation of AID expression in the immune response.	The Journal of experimental medicine	2007	87
17664295	Cytidine	Langerak P	A/T mutagenesis in hypermutated immunoglobulin genes strongly depends on PCNAK164 modification.	The Journal of experimental medicine	2007	59
18066064	Cytidine	Pasqualucci L	AID is required for germinal center-derived lymphomagenesis.	Nature genetics	2008	135
18678733	Cytidine	Takizawa M	AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor development.	The Journal of experimental medicine	2008	71
19070574	Cytidine	Robbiani DF	AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations.	Cell	2008	156
24200695	Cytidine	Caganova M	Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis.	The Journal of clinical investigation	2013	46
24670820	Cytidine	Olivier M	Modelling mutational landscapes of human cancers in vitro.	Scientific reports	2014	20
25483776	Cytidine	Meng FL	Convergent transcription at intragenic super-enhancers targets AID-initiated genomic instability.	Cell	2014	54
25483777	Cytidine	Qian J	B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity.	Cell	2014	71
26276629	Cytidine	Robbiani DF	Plasmodium Infection Promotes Genomic Instability and AID-Dependent B Cell Lymphoma.	Cell	2015	29
8402885	Antineoplastic Agents	Lowe SW	p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.	Cell	1993	453
10363983	Antineoplastic Agents	Adams J	Proteasome inhibitors: a novel class of potent and effective antitumor agents.	Cancer research	1999	244
14561896	Antineoplastic Agents	Bocci G	Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy.	Proceedings of the National Academy of Sciences of the United States of America	2003	88
15523088	Antineoplastic Agents	Studeny M	Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.	Journal of the National Cancer Institute	2004	237
16618762	Antineoplastic Agents	Heltweg B	Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes.	Cancer research	2006	120
16868082	Antineoplastic Agents	Kinoshita M	Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption.	Proceedings of the National Academy of Sciences of the United States of America	2006	151
18260118	Antineoplastic Agents	Kolb EA	Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program.	Pediatric blood & cancer	2008	60
18381444	Antineoplastic Agents	Rhodes N	Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.	Cancer research	2008	83
19236065	Antineoplastic Agents	Bhirde AA	Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery.	ACS nano	2009	102
20215516	Antineoplastic Agents	Jin Y	Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species.	Cancer research	2010	92
20471303	Antineoplastic Agents	Lai SY	Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.	Drug resistance updates 	2010	44
20980833	Antineoplastic Agents	Vucicevic L	Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway.	Autophagy	2011	44
21042421	Antineoplastic Agents	Sriram MI	Antitumor activity of silver nanoparticles in Dalton's lymphoma ascites tumor model.	International journal of nanomedicine	2010	43
22532596	Antineoplastic Agents	Vinay DS	Immunotherapy of cancer with 4-1BB.	Molecular cancer therapeutics	2012	38
22588880	Antineoplastic Agents	Ni J	Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent.	Cancer discovery	2012	56
22689530	Antineoplastic Agents	Liu Y	A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo.	Molecular cancer therapeutics	2012	78
23303345	Antineoplastic Agents	Balaburski GM	A modified HSP70 inhibitor shows broad activity as an anticancer agent.	Molecular cancer research 	2013	33
23674815	Antineoplastic Agents	Clem BF	Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.	Molecular cancer therapeutics	2013	45
24130167	Antineoplastic Agents	Akinyeke T	Metformin targets c-MYC oncogene to prevent prostate cancer.	Carcinogenesis	2013	36
25028336	Antineoplastic Agents	Yallapu MM	Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer.	Biomaterials	2014	25
25043604	Antineoplastic Agents	Mason JM	Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent.	Cancer cell	2014	27
25712124	Antineoplastic Agents	Prabhu VV	Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.	Cancer research	2015	30
27635045	Antineoplastic Agents	Wallace EM	A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma.	Cancer research	2016	17
10224280	Fluorouracil	Li S	The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.	The Journal of experimental medicine	1999	131
10411544	Fluorouracil	Ashkenazi A	Safety and antitumor activity of recombinant soluble Apo2 ligand.	The Journal of clinical investigation	1999	416
12359756	Fluorouracil	Pietras K	Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.	Cancer research	2002	106
15550486	Fluorouracil	Mancini SJ	Jagged1-dependent Notch signaling is dispensable for hematopoietic stem cell self-renewal and differentiation.	Blood	2005	88
19212321	Fluorouracil	Essers MA	IFNalpha activates dormant haematopoietic stem cells in vivo.	Nature	2009	351
19244128	Fluorouracil	Dallas NA	Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition.	Cancer research	2009	149
19276252	Fluorouracil	Sakamoto K	Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth.	Clinical cancer research 	2009	62
19402749	Fluorouracil	Kunz C	Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil.	PLoS biology	2009	53
19483695	Fluorouracil	Sato T	Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion.	Nature medicine	2009	112
19497284	Fluorouracil	Hofmann I	Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis.	Cell stem cell	2009	59
19622726	Fluorouracil	Yoo BK	Identification of genes conferring resistance to 5-fluorouracil.	Proceedings of the National Academy of Sciences of the United States of America	2009	57
20697159	Fluorouracil	Haraguchi N	CD13 is a therapeutic target in human liver cancer stem cells.	The Journal of clinical investigation	2010	135
22117060	Fluorouracil	Ma K	DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression.	The Journal of biological chemistry	2012	36
23934972	Fluorouracil	Spitzner M	STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo.	International journal of cancer	2014	21
24747973	Fluorouracil	Eden CJ	Orthotopic models of pediatric brain tumors in zebrafish.	Oncogene	2015	15
24885567	Fluorouracil	Du T	Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway.	Molecular cancer	2014	21
25342715	Fluorouracil	Scheicher R	CDK6 as a key regulator of hematopoietic and leukemic stem cell activation.	Blood	2015	26
25686605	Fluorouracil	Busch K	Fundamental properties of unperturbed haematopoiesis from stem cells in vivo.	Nature	2015	106
25820415	Fluorouracil	Kawai T	Keratin 19, a Cancer Stem Cell Marker in Human Hepatocellular Carcinoma.	Clinical cancer research 	2015	23
26494468	Fluorouracil	Alam SK	DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53.	Cell death and differentiation	2016	11
27095304	Fluorouracil	Zhao M	miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K/AKT-c-JUN.	Nature communications	2016	16
27865009	Fluorouracil	Gao Y	Melatonin synergizes the chemotherapeutic effect of 5-fluorouracil in colon cancer by suppressing PI3K/AKT and NF-κB/iNOS signaling pathways.	Journal of pineal research	2017	10
10391249	Cisplatin	Gong JG	The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage.	Nature	1999	223
10843985	Cisplatin	Bhattacharyya A	The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin.	The Journal of biological chemistry	2000	158
17292828	Cisplatin	Reinhardt HC	p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage.	Cancer cell	2007	174
18162465	Cisplatin	Pabla N	ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis.	The Journal of biological chemistry	2008	98
18206965	Cisplatin	Lim ST	Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation.	Molecular cell	2008	151
18316592	Cisplatin	Ohta T	Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth.	Cancer research	2008	174
18418074	Cisplatin	Borst P	How do real tumors become resistant to cisplatin?	Cell cycle	2008	51
18451150	Cisplatin	Shafee N	Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors.	Cancer research	2008	99
19657384	Cisplatin	Cerniglia GJ	Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy.	PloS one	2009	47
19783996	Cisplatin	Gonfloni S	Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death.	Nature medicine	2009	79
19805294	Cisplatin	Bertolini G	Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.	Proceedings of the National Academy of Sciences of the United States of America	2009	248
20145120	Cisplatin	Holland SJ	R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.	Cancer research	2010	121
20196784	Cisplatin	Harhaji-Trajkovic L	AMPK-mediated autophagy inhibits apoptosis in cisplatin-treated tumour cells.	Journal of cellular and molecular medicine	2009	58
20215556	Cisplatin	Sikora AG	Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy.	Clinical cancer research 	2010	43
20304803	Cisplatin	Kang TH	Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase.	Proceedings of the National Academy of Sciences of the United States of America	2010	68
20395368	Cisplatin	Oliver TG	Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer.	Genes & development	2010	66
20530669	Cisplatin	Jiang T	High levels of Nrf2 determine chemoresistance in type II endometrial cancer.	Cancer research	2010	80
21068376	Cisplatin	Doles J	Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy.	Proceedings of the National Academy of Sciences of the United States of America	2010	62
21068378	Cisplatin	Xie K	Error-prone translesion synthesis mediates acquired chemoresistance.	Proceedings of the National Academy of Sciences of the United States of America	2010	67
21124918	Cisplatin	Leung EL	Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties.	PloS one	2010	115
21266349	Cisplatin	Liccardi G	EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment.	Cancer research	2011	73
21353530	Cisplatin	Otvos L Jr	Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer.	European journal of cancer	2011	38
21472714	Cisplatin	Alhazzazi TY	Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer.	Cancer	2011	53
21532889	Cisplatin	Rattan R	Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo.	Neoplasia	2011	85
21633170	Cisplatin	Pabla N	Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer.	The Journal of clinical investigation	2011	47
21726833	Cisplatin	Lee TK	CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation.	Cell stem cell	2011	148
21765211	Cisplatin	Lesterhuis WJ	Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.	The Journal of clinical investigation	2011	41
21909139	Cisplatin	Yue P	Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.	Oncogene	2012	43
22157765	Cisplatin	Zou Z	MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy.	The Journal of biological chemistry	2012	47
22440905	Cisplatin	Zager RA	Plasma and urinary heme oxygenase-1 in AKI.	Journal of the American Society of Nephrology 	2012	33
22516258	Cisplatin	Nakasone ES	Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance.	Cancer cell	2012	112
22696230	Cisplatin	Chung LY	Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2.	Clinical cancer research 	2012	37
23251001	Cisplatin	Kimple RJ	Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts.	Clinical cancer research 	2013	31
23524583	Cisplatin	Zhang S	Generation of cancer stem-like cells through the formation of polyploid giant cancer cells.	Oncogene	2014	58
23537295	Cisplatin	Abubaker K	Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.	Molecular cancer	2013	55
24115572	Cisplatin	Pereira L	Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK.	EMBO molecular medicine	2013	28
24165223	Cisplatin	Sun XP	Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.	The FEBS journal	2014	20
24240701	Cisplatin	Shin DH	SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin.	Cancer research	2014	20
24502656	Cisplatin	Lu L	Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.	Journal of translational medicine	2014	25
24560445	Cisplatin	Topp MD	Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts.	Molecular oncology	2014	30
24583641	Cisplatin	Phesse TJ	Endogenous c-Myc is essential for p53-induced apoptosis in response to DNA damage in vivo.	Cell death and differentiation	2014	27
24747074	Cisplatin	Chian S	Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo.	Biochemical and biophysical research communications	2014	23
25026298	Cisplatin	Ha K	Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.	Oncotarget	2014	25
25114235	Cisplatin	Xue W	Small RNA combination therapy for lung cancer.	Proceedings of the National Academy of Sciences of the United States of America	2014	56
25483077	Cisplatin	Yano S	Tumor-targeting Salmonella typhimurium A1-R decoys quiescent cancer cells to cycle as visualized by FUCCI imaging and become sensitive to chemotherapy.	Cell cycle	2014	43
25537512	Cisplatin	Chiu WT	FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.	Oncotarget	2015	35
25650716	Cisplatin	He J	Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy.	Autophagy	2015	22
25658419	Cisplatin	Xu J	β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells.	PloS one	2015	18
25871396	Cisplatin	Ma SR	Anterior gradient protein 2 expression in high grade head and neck squamous cell carcinoma correlated with cancer stem cell and epithelial mesenchymal transition.	Oncotarget	2015	20
25995442	Cisplatin	Liu G	Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.	Journal of the National Cancer Institute	2015	24
26020117	Cisplatin	Cioffi M	Identification of a distinct population of CD133(+)CXCR4(+) cancer stem cells in ovarian cancer.	Scientific reports	2015	22
26654944	Cisplatin	Choi EJ	FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells.	Oncotarget	2016	12
26722380	Cisplatin	Yang T	Anti-tumor Efficiency of Lipid-coated Cisplatin Nanoparticles Co-loaded with MicroRNA-375.	Theranostics	2016	18
26859293	Cisplatin	Su YC	Galectin-1-Induced Autophagy Facilitates Cisplatin Resistance of Hepatocellular Carcinoma.	PloS one	2016	11
27381626	Cisplatin	Ter Brugge P	Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.	Journal of the National Cancer Institute	2016	11
27569212	Cisplatin	Beyranvand Nejad E	Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells.	Cancer research	2016	10
27803105	Cisplatin	Yokoyama Y	BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer.	Cancer research	2016	13
28407783	Cisplatin	Zheng P	Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells.	Journal of experimental & clinical cancer research 	2017	15
15082532	Diethylnitrosamine	Kalinichenko VV	Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor.	Genes & development	2004	143
15492232	Diethylnitrosamine	Yamamoto Y	The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice.	Cancer research	2004	84
15565109	Diethylnitrosamine	Lee JS	Application of comparative functional genomics to identify best-fit mouse models to study human cancer.	Nature genetics	2004	150
15989949	Diethylnitrosamine	Maeda S	IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis.	Cell	2005	334
16807293	Diethylnitrosamine	Sakurai T	Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation.	Proceedings of the National Academy of Sciences of the United States of America	2006	129
17615358	Diethylnitrosamine	Naugler WE	Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.	Science	2007	486
19996281	Diethylnitrosamine	Fan Y	The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis.	Cancer research	2010	51
20432254	Diethylnitrosamine	Nejak-Bowen KN	Accelerated liver regeneration and hepatocarcinogenesis in mice overexpressing serine-45 mutant beta-catenin.	Hepatology	2010	58
21440549	Diethylnitrosamine	Yang H	A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression.	Gastroenterology	2011	36
21465510	Diethylnitrosamine	Park O	In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression.	Hepatology	2011	65
21575863	Diethylnitrosamine	Bard-Chapeau EA	Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis.	Cancer cell	2011	87
21674558	Diethylnitrosamine	Jiang R	Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3.	Hepatology	2011	64
21778049	Diethylnitrosamine	Monnier J	CXCR7 is up-regulated in human and murine hepatocellular carcinoma and is specifically expressed by endothelial cells.	European journal of cancer	2012	33
22267597	Diethylnitrosamine	Schneider C	Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer.	Gut	2012	32
22473819	Diethylnitrosamine	Callegari E	Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model.	Hepatology	2012	50
22689379	Diethylnitrosamine	Srivastava J	Astrocyte elevated gene-1 promotes hepatocarcinogenesis: novel insights from a mouse model.	Hepatology	2012	36
22719066	Diethylnitrosamine	Wu J	The proinflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocellular carcinoma.	Cancer research	2012	44
22859216	Diethylnitrosamine	Lin H	Loss of immunity-supported senescence enhances susceptibility to hepatocellular carcinogenesis and progression in Toll-like receptor 2-deficient mice.	Hepatology	2013	26
22898879	Diethylnitrosamine	Wu K	Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development.	Hepatology	2012	45
23175466	Diethylnitrosamine	Dill MT	Constitutive Notch2 signaling induces hepatic tumors in mice.	Hepatology	2013	36
23315968	Diethylnitrosamine	Walesky C	Hepatocyte nuclear factor 4 alpha deletion promotes diethylnitrosamine-induced hepatocellular carcinoma in rodents.	Hepatology	2013	28
23391818	Diethylnitrosamine	Yang L	Transforming growth factor-β signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1.	Gastroenterology	2013	31
23813475	Diethylnitrosamine	Bertran E	Overactivation of the TGF-β pathway confers a mesenchymal-like phenotype and CXCR4-dependent migratory properties to liver tumor cells.	Hepatology	2013	31
24582836	Diethylnitrosamine	Lau CC	Viral-human chimeric transcript predisposes risk to liver cancer development and progression.	Cancer cell	2014	50
25010260	Diethylnitrosamine	Perra A	YAP activation is an early event and a potential therapeutic target in liver cancer development.	Journal of hepatology	2014	49
25879839	Diethylnitrosamine	Wilson CL	NFκB1 is a suppressor of neutrophil-driven hepatocellular carcinoma.	Nature communications	2015	17
26028023	Diethylnitrosamine	Chen CC	The matricellular protein CCN1 suppresses hepatocarcinogenesis by inhibiting compensatory proliferation.	Oncogene	2016	14
16723399	irinotecan	Agrelo R	Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer.	Proceedings of the National Academy of Sciences of the United States of America	2006	74
18560594	irinotecan	Dylla SJ	Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy.	PloS one	2008	174
19470791	irinotecan	Piazza GA	A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity.	Cancer prevention research	2009	45
20167811	irinotecan	de Groot JF	Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.	Neuro-oncology	2010	166
21051639	irinotecan	Wallace BD	Alleviating cancer drug toxicity by inhibiting a bacterial enzyme.	Science	2010	122
22446188	irinotecan	Ma CX	Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.	The Journal of clinical investigation	2012	63
23081779	irinotecan	Kobayashi S	LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution.	Stem cells	2012	38
17611683	Paclitaxel	Kajiyama H	Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells.	International journal of oncology	2007	127
18617895	Paclitaxel	Yuan M	Yes-associated protein (YAP) functions as a tumor suppressor in breast.	Cell death and differentiation	2008	79
19665763	Paclitaxel	Inaba T	Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma.	Gynecologic oncology	2009	47
20332234	Paclitaxel	To K	Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance.	Cancer research	2010	49
21204585	Paclitaxel	Sun TM	Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression.	ACS nano	2011	67
21763756	Paclitaxel	Chen Y	Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain.	Neuroscience	2011	57
22039576	Paclitaxel	DeNardo DG	Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.	Cancer discovery	2011	404
22335738	Paclitaxel	Stone RL	Paraneoplastic thrombocytosis in ovarian cancer.	The New England journal of medicine	2012	130
23208505	Paclitaxel	Lock FE	Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche.	Oncogene	2013	49
23359505	Paclitaxel	Sevko A	Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model.	Journal of immunology	2013	31
23871962	Paclitaxel	Swaminathan SK	CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer.	Journal of controlled release 	2013	27
23943797	Paclitaxel	Cieply B	Epithelial-mesenchymal transition and tumor suppression are controlled by a reciprocal feedback loop between ZEB1 and Grainyhead-like-2.	Cancer research	2013	39
24170767	Paclitaxel	Liu N	BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.	Molecular cancer therapeutics	2013	32
24632940	Paclitaxel	Wang B	Microtubule acetylation amplifies p38 kinase signalling and anti-inflammatory IL-10 production.	Nature communications	2014	23
24909985	Paclitaxel	Affara NI	B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas.	Cancer cell	2014	58
25900794	Paclitaxel	Hu Y	miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.	Breast cancer research and treatment	2015	20
25961928	Paclitaxel	Khongkow P	Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance.	Oncogene	2016	22
26071354	Paclitaxel	Chen MB	MicroRNA-101 down-regulates sphingosine kinase 1 in colorectal cancer cells.	Biochemical and biophysical research communications	2015	28
26421710	Paclitaxel	Farnie G	High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant.	Oncotarget	2015	30
26424893	Paclitaxel	Li Y	The Cancer Chemotherapeutic Paclitaxel Increases Human and Rodent Sensory Neuron Responses to TRPV1 by Activation of TLR4.	The Journal of neuroscience 	2015	33
26494857	Paclitaxel	Cesca M	Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response.	Molecular cancer therapeutics	2016	13
26573793	Paclitaxel	Peng J	Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer.	Cancer research	2015	24
28209618	Paclitaxel	Chen MW	The STAT3-miRNA-92-Wnt Signaling Pathway Regulates Spheroid Formation and Malignant Progression in Ovarian Cancer.	Cancer research	2017	7
9501191	Tamoxifen	Lavinsky RM	Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.	Proceedings of the National Academy of Sciences of the United States of America	1998	112
10411913	Tamoxifen	Vasioukhin V	The magical touch: genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin.	Proceedings of the National Academy of Sciences of the United States of America	1999	237
14517555	Tamoxifen	Balbín M	Loss of collagenase-2 confers increased skin tumor susceptibility to male mice.	Nature genetics	2003	119
15187022	Tamoxifen	Göthert JR	Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium.	Blood	2004	86
15716339	Tamoxifen	Andreu P	Crypt-restricted proliferation and commitment to the Paneth cell lineage following Apc loss in the mouse intestine.	Development	2005	84
17932118	Tamoxifen	Lantinga-van Leeuwen IS	Kidney-specific inactivation of the Pkd1 gene induces rapid cyst formation in developing kidneys and a slow onset of disease in adult mice.	Human molecular genetics	2007	63
18257043	Tamoxifen	Claxton S	Efficient, inducible Cre-recombinase activation in vascular endothelium.	Genesis	2008	79
18263895	Tamoxifen	Patel V	Acute kidney injury and aberrant planar cell polarity induce cyst formation in mice lacking renal cilia.	Human molecular genetics	2008	128
18391070	Tamoxifen	Weis SM	Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK.	The Journal of cell biology	2008	65
20495363	Tamoxifen	Bonuccelli G	The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts.	Cell cycle	2010	73
21048142	Tamoxifen	Konopka W	MicroRNA loss enhances learning and memory in mice.	The Journal of neuroscience 	2010	103
21521783	Tamoxifen	Nguyen AT	DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.	Blood	2011	66
23143302	Tamoxifen	Nishio M	Cancer susceptibility and embryonic lethality in Mob1a/1b double-mutant mice.	The Journal of clinical investigation	2012	37
23589310	Tamoxifen	Khurana SS	The hyaluronic acid receptor CD44 coordinates normal and metaplastic gastric epithelial progenitor cell proliferation.	The Journal of biological chemistry	2013	32
24746818	Tamoxifen	Luo X	Isolation and molecular characterization of circulating melanoma cells.	Cell reports	2014	32
25474590	Tamoxifen	Zhou X	Chondrocytes transdifferentiate into osteoblasts in endochondral bone during development, postnatal growth and fracture healing in mice.	PLoS genetics	2014	70
25480918	Tamoxifen	López-Arribillaga E	Bmi1 regulates murine intestinal stem cell proliferation and self-renewal downstream of Notch.	Development	2015	19
25580734	Tamoxifen	Zhou W	Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth.	Nature cell biology	2015	88
25964370	Tamoxifen	Walker JA	Bcl11b is essential for group 2 innate lymphoid cell development.	The Journal of experimental medicine	2015	37
26112022	Tamoxifen	Pérez-Medina C	PET Imaging of Tumor-Associated Macrophages with 89Zr-Labeled High-Density Lipoprotein Nanoparticles.	Journal of nuclear medicine 	2015	15
26341973	Tamoxifen	Jing Y	Chondrocytes Directly Transform into Bone Cells in Mandibular Condyle Growth.	Journal of dental research	2015	17
26538583	Tamoxifen	Tran KA	Endothelial β-Catenin Signaling Is Required for Maintaining Adult Blood-Brain Barrier Integrity and Central Nervous System Homeostasis.	Circulation	2016	11
26592447	Tamoxifen	Bailey JM	p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells.	Oncogene	2016	13
27977766	Tamoxifen	Liu H	Knockdown of Long Non-Coding RNA UCA1 Increases the Tamoxifen Sensitivity of Breast Cancer Cells through Inhibition of Wnt/β-Catenin Pathway.	PloS one	2016	12
9064324	Oligonucleotides, Antisense	O'Connell J	The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.	The Journal of experimental medicine	1996	134
15895073	Oligonucleotides, Antisense	Chiarle R	Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target.	Nature medicine	2005	134
18431520	Oligonucleotides, Antisense	Ernst M	STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice.	The Journal of clinical investigation	2008	93
19509158	Oligonucleotides, Antisense	Li J	MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor.	Clinical cancer research 	2009	102
21358643	Oligonucleotides, Antisense	Polymenidou M	Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43.	Nature neuroscience	2011	316
23766514	Oligonucleotides, Antisense	Li J	Microvesicle-mediated transfer of microRNA-150 from monocytes to endothelial cells promotes angiogenesis.	The Journal of biological chemistry	2013	42
24170860	Oligonucleotides, Antisense	Lagier-Tourenne C	Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration.	Proceedings of the National Academy of Sciences of the United States of America	2013	126
25223704	Oligonucleotides, Antisense	Yin Y	Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth.	Cell research	2014	30
25639539	Oligonucleotides, Antisense	Zhao Y	Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer.	Targeted oncology	2015	23
25970242	Oligonucleotides, Antisense	Koh CM	MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis.	Nature	2015	46
26282675	Oligonucleotides, Antisense	Wu H	MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway.	Gut	2016	17
27281208	Oligonucleotides, Antisense	Fox RG	Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma.	Nature	2016	16
28017471	Oligonucleotides, Antisense	d'Ydewalle C	The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy.	Neuron	2017	5
1680859	Phosphatidylinositols	Caughey B	The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive.	The Journal of biological chemistry	1991	157
2987699	Phosphatidylinositols	Whitman M	Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation.	Nature	1985	230
9671496	Phosphatidylinositols	Murphy MA	Tissue hyperplasia and enhanced T-cell signalling via ZAP-70 in c-Cbl-deficient mice.	Molecular and cellular biology	1998	104
10497129	Phosphatidylinositols	Di Cristofano A	Impaired Fas response and autoimmunity in Pten+/- mice.	Science	1999	117
10611246	Phosphatidylinositols	Lee RJ	Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway.	Molecular and cellular biology	2000	96
11470893	Phosphatidylinositols	Enari M	Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody.	Proceedings of the National Academy of Sciences of the United States of America	2001	106
12124177	Phosphatidylinositols	Sattler M	Critical role for Gab2 in transformation by BCR/ABL.	Cancer cell	2002	93
12748302	Phosphatidylinositols	Hamilton TG	Evolutionary divergence of platelet-derived growth factor alpha receptor signaling mechanisms.	Molecular and cellular biology	2003	119
16091473	Phosphatidylinositols	Takeshita F	Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2005	91
16169464	Phosphatidylinositols	Stanger BZ	Pten constrains centroacinar cell expansion and malignant transformation in the pancreas.	Cancer cell	2005	112
16339315	Phosphatidylinositols	Zhao JJ	The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.	Proceedings of the National Academy of Sciences of the United States of America	2005	128
16446424	Phosphatidylinositols	Furuya F	Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor.	Proceedings of the National Academy of Sciences of the United States of America	2006	65
16456542	Phosphatidylinositols	Takahashi Y	PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling.	The EMBO journal	2006	76
16489002	Phosphatidylinositols	Klos KS	ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.	Cancer research	2006	61
17060635	Phosphatidylinositols	Zhao JJ	The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation.	Proceedings of the National Academy of Sciences of the United States of America	2006	80
17210696	Phosphatidylinositols	Maroulakou IG	Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice.	Cancer research	2007	108
17308108	Phosphatidylinositols	Sawada K	c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.	Cancer research	2007	92
17372210	Phosphatidylinositols	Mehrian-Shai R	Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	62
17900104	Phosphatidylinositols	Hilder TL	Proteomic identification of the cerebral cavernous malformation signaling complex.	Journal of proteome research	2007	58
18082964	Phosphatidylinositols	Fraser MM	Phosphatase and tensin homolog, deleted on chromosome 10 deficiency in brain causes defects in synaptic structure, transmission and plasticity, and myelination abnormalities.	Neuroscience	2008	64
18296647	Phosphatidylinositols	Schmid T	Translation inhibitor Pdcd4 is targeted for degradation during tumor promotion.	Cancer research	2008	53
18328427	Phosphatidylinositols	Kleber S	Yes and PI3K bind CD95 to signal invasion of glioblastoma.	Cancer cell	2008	88
18794877	Phosphatidylinositols	Endersby R	PTEN signaling in brain: neuropathology and tumorigenesis.	Oncogene	2008	69
19176381	Phosphatidylinositols	Almog N	Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype.	Cancer research	2009	73
19272022	Phosphatidylinositols	Ooms LM	The role of the inositol polyphosphate 5-phosphatases in cellular function and human disease.	The Biochemical journal	2009	72
19279572	Phosphatidylinositols	Kalaany NY	Tumours with PI3K activation are resistant to dietary restriction.	Nature	2009	128
19351816	Phosphatidylinositols	Miller KA	Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo.	Cancer research	2009	47
19491266	Phosphatidylinositols	Dillon RL	Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression.	Cancer research	2009	57
19567914	Phosphatidylinositols	Schoeberl B	Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.	Science signaling	2009	114
19602587	Phosphatidylinositols	Huang J	Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.	Cancer research	2009	46
20010698	Phosphatidylinositols	Maes C	Increased skeletal VEGF enhances beta-catenin activity and results in excessively ossified bones.	The EMBO journal	2010	48
20081861	Phosphatidylinositols	Houghton AM	Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth.	Nature medicine	2010	120
20388916	Phosphatidylinositols	Poliseno L	Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation.	Science signaling	2010	166
20424120	Phosphatidylinositols	Dillon RL	Distinct biological roles for the akt family in mammary tumor progression.	Cancer research	2010	60
20686178	Phosphatidylinositols	Andersen JN	Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.	Science translational medicine	2010	57
20807812	Phosphatidylinositols	Hill R	PTEN loss accelerates KrasG12D-induced pancreatic cancer development.	Cancer research	2010	60
21324922	Phosphatidylinositols	Adams JR	Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation.	Cancer research	2011	38
21613208	Phosphatidylinositols	Suvasini R	Insulin growth factor-2 binding protein 3 (IGF2BP3) is a glioblastoma-specific marker that activates phosphatidylinositol 3-kinase/mitogen-activated protein kinase (PI3K/MAPK) pathways by modulating IGF-2.	The Journal of biological chemistry	2011	38
21628414	Phosphatidylinositols	Kuchenbauer F	Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells.	Blood	2011	38
21670491	Phosphatidylinositols	Hart JR	Phosphorylation of AKT: a mutational analysis.	Oncotarget	2011	37
21822287	Phosphatidylinositols	Liu P	Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.	Nature medicine	2011	93
21900500	Phosphatidylinositols	Alam H	Novel function of keratins 5 and 14 in proliferation and differentiation of stratified epithelial cells.	Molecular biology of the cell	2011	37
23318419	Phosphatidylinositols	Brouxhon SM	Soluble E-cadherin: a critical oncogene modulating receptor tyrosine kinases, MAPK and PI3K/Akt/mTOR signaling.	Oncogene	2014	22
24569712	Phosphatidylinositols	Nakahata S	Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers.	Nature communications	2014	28
24762440	Phosphatidylinositols	Yang Y	ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism.	The Journal of clinical investigation	2014	40
25001183	Phosphatidylinositols	Hu J	microRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C.	European journal of cancer	2014	33
25183785	Phosphatidylinositols	Rubashkin MG	Force engages vinculin and promotes tumor progression by enhancing PI3K activation of phosphatidylinositol (3,4,5)-triphosphate.	Cancer research	2014	41
25534823	Phosphatidylinositols	Kaul A	Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.	Neuro-oncology	2015	17
25650317	Phosphatidylinositols	Ghosh JC	Adaptive mitochondrial reprogramming and resistance to PI3K therapy.	Journal of the National Cancer Institute	2015	27
25976245	Phosphatidylinositols	Crespo I	Molecular and Genomic Alterations in Glioblastoma Multiforme.	The American journal of pathology	2015	19
27199435	Phosphatidylinositols	Quail DF	The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.	Science	2016	42
8646779	Sirolimus	Nakayama K	Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors.	Cell	1996	378
11359907	Sirolimus	Laughner E	HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression.	Molecular and cellular biology	2001	265
11821896	Sirolimus	Guba M	Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.	Nature medicine	2002	312
11875047	Sirolimus	Kwiatkowski DJ	A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells.	Human molecular genetics	2002	224
12039858	Sirolimus	Humar R	Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling.	FASEB journal 	2002	89
14561707	Sirolimus	Zhang H	Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.	The Journal of clinical investigation	2003	206
15029198	Sirolimus	Wendel HG	Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy.	Nature	2004	282
15156201	Sirolimus	Majumder PK	mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.	Nature medicine	2004	282
15705789	Sirolimus	Hammerman PS	Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival.	Blood	2005	74
15805275	Sirolimus	Dasgupta B	Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors.	Cancer research	2005	81
15937108	Sirolimus	Johannessen CM	The NF1 tumor suppressor critically regulates TSC2 and mTOR.	Proceedings of the National Academy of Sciences of the United States of America	2005	158
16598206	Sirolimus	Yilmaz OH	Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells.	Nature	2006	469
16715125	Sirolimus	Wang X	Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation.	Oncogene	2006	77
16799564	Sirolimus	Androutsellis-Theotokis A	Notch signalling regulates stem cell numbers in vitro and in vivo.	Nature	2006	271
16904612	Sirolimus	Sodhi A	The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor.	Cancer cell	2006	65
16915281	Sirolimus	Bernardi R	PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR.	Nature	2006	132
17082322	Sirolimus	Sin SH	Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling.	Blood	2007	67
17290308	Sirolimus	Zhang H	PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.	The Journal of clinical investigation	2007	121
17363557	Sirolimus	Mabuchi S	RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.	Cancer research	2007	59
17496901	Sirolimus	Hernando E	The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas.	Nature medicine	2007	78
18164202	Sirolimus	Johannessen CM	TORC1 is essential for NF1-associated malignancies.	Current biology 	2008	69
18198340	Sirolimus	DeYoung MP	Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling.	Genes & development	2008	222
18354499	Sirolimus	Knutson SK	Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks.	The EMBO journal	2008	92
18389497	Sirolimus	Zeng LH	Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.	Annals of neurology	2008	184
18495876	Sirolimus	Meikle L	Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.	The Journal of neuroscience 	2008	168
18568033	Sirolimus	Ehninger D	Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis.	Nature medicine	2008	270
18650380	Sirolimus	Schewe DM	ATF6alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2008	67
18664580	Sirolimus	Mills JR	mTORC1 promotes survival through translational control of Mcl-1.	Proceedings of the National Academy of Sciences of the United States of America	2008	112
18684977	Sirolimus	Golovina TN	CD28 costimulation is essential for human T regulatory expansion and function.	Journal of immunology	2008	55
18713735	Sirolimus	Schieke SM	Mitochondrial metabolism modulates differentiation and teratoma formation capacity in mouse embryonic stem cells.	The Journal of biological chemistry	2008	56
18725988	Sirolimus	Carracedo A	Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.	The Journal of clinical investigation	2008	507
18768809	Sirolimus	Fujishita T	Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice.	Proceedings of the National Academy of Sciences of the United States of America	2008	57
18848473	Sirolimus	Weichhart T	The TSC-mTOR signaling pathway regulates the innate inflammatory response.	Immunity	2008	197
19185849	Sirolimus	Guertin DA	mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice.	Cancer cell	2009	149
19261747	Sirolimus	Puzio-Kuter AM	Inactivation of p53 and Pten promotes invasive bladder cancer.	Genes & development	2009	98
19282848	Sirolimus	Dankort D	Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.	Nature genetics	2009	324
19420259	Sirolimus	Di Nardo A	Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner.	The Journal of neuroscience 	2009	63
19451225	Sirolimus	James MF	NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.	Molecular and cellular biology	2009	69
19587680	Sirolimus	Harrison DE	Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.	Nature	2009	1055
19773376	Sirolimus	Kim KW	Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model.	Clinical cancer research 	2009	47
19817806	Sirolimus	Wong M	Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.	Epilepsia	2010	59
19934433	Sirolimus	Chen C	mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells.	Science signaling	2009	181
20008787	Sirolimus	Kharas MG	Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.	Blood	2010	90
20008935	Sirolimus	Olive V	miR-19 is a key oncogenic component of mir-17-92.	Genes & development	2009	235
20038814	Sirolimus	Ma J	Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade.	The Journal of clinical investigation	2010	76
20038818	Sirolimus	Tsang CK	mTOR binds to the promoters of RNA polymerase I- and III-transcribed genes.	Cell cycle	2010	47
20042677	Sirolimus	Deng L	A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis.	The American journal of pathology	2010	57
20072130	Sirolimus	Janes MR	Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.	Nature medicine	2010	137
20080688	Sirolimus	Hung KE	Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment.	Proceedings of the National Academy of Sciences of the United States of America	2010	80
20080710	Sirolimus	Alain T	Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production.	Proceedings of the National Academy of Sciences of the United States of America	2010	46
20139716	Sirolimus	Blagosklonny MV	Calorie restriction: decelerating mTOR-driven aging from cells to organisms (including humans).	Cell cycle	2010	85
20363920	Sirolimus	Anisimov VN	Rapamycin extends maximal lifespan in cancer-prone mice.	The American journal of pathology	2010	107
20371474	Sirolimus	Amin DN	Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.	Science translational medicine	2010	69
20498714	Sirolimus	Squarize CH	Accelerated wound healing by mTOR activation in genetically defined mouse models.	PloS one	2010	40
20563248	Sirolimus	Molina JR	Invasive glioblastoma cells acquire stemness and increased Akt activation.	Neoplasia	2010	62
20686120	Sirolimus	Hoang B	Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.	Blood	2010	42
20876733	Sirolimus	Lee DY	Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner.	Genes & development	2010	49
20890040	Sirolimus	Schreiber TH	Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation.	The Journal of clinical investigation	2010	51
20978191	Sirolimus	Zhang F	mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis.	Cancer research	2010	49
21062901	Sirolimus	Zeng LH	Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.	Human molecular genetics	2011	70
21076392	Sirolimus	Balamurugan K	The tumour suppressor C/EBPδ inhibits FBXW7 expression and promotes mammary tumour metastasis.	The EMBO journal	2010	43
21079150	Sirolimus	Zhang S	Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production.	Blood	2011	52
21147110	Sirolimus	Calvisi DF	Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.	Gastroenterology	2011	98
21289308	Sirolimus	Yoshimi A	Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins.	Blood	2011	35
21357822	Sirolimus	Shende P	Cardiac raptor ablation impairs adaptive hypertrophy, alters metabolic gene expression, and causes heart failure in mice.	Circulation	2011	72
21383697	Sirolimus	Oneyama C	MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways.	Oncogene	2011	44
21403402	Sirolimus	Feliciano DM	Single-cell Tsc1 knockout during corticogenesis generates tuber-like lesions and reduces seizure threshold in mice.	The Journal of clinical investigation	2011	54
21413931	Sirolimus	Pearce LR	Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney.	The Biochemical journal	2011	53
21501832	Sirolimus	Jaramillo M	Leishmania repression of host translation through mTOR cleavage is required for parasite survival and infection.	Cell host & microbe	2011	43
21564534	Sirolimus	Hippen KL	Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease.	American journal of transplantation 	2011	88
21670596	Sirolimus	Oh WJ	mTOR complex 2 signaling and functions.	Cell cycle	2011	154
21746920	Sirolimus	Parkhitko A	Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent.	Proceedings of the National Academy of Sciences of the United States of America	2011	79
21804531	Sirolimus	Peña-Llopis S	Regulation of TFEB and V-ATPases by mTORC1.	The EMBO journal	2011	122
21907282	Sirolimus	Carson RP	Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin.	Neurobiology of disease	2012	57
21975930	Sirolimus	Patel V	Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer.	Cancer research	2011	52
21993994	Sirolimus	Ho C	AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways.	Hepatology	2012	55
22107964	Sirolimus	Anisimov VN	Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice.	Cell cycle	2011	137
22186785	Sirolimus	Criollo A	Autophagy is required for the activation of NFκB.	Cell cycle	2012	31
22234835	Sirolimus	Fang Y	MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma.	Hepatology	2012	103
22287548	Sirolimus	Chen W	Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway.	Cancer research	2012	37
22290600	Sirolimus	De Angel RE	The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001.	Molecular carcinogenesis	2013	26
22409888	Sirolimus	Molinolo AA	mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.	Clinical cancer research 	2012	38
22422409	Sirolimus	Meric-Bernstam F	PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.	Clinical cancer research 	2012	67
22457330	Sirolimus	Menon S	Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice.	Science signaling	2012	51
22504094	Sirolimus	Chang Y	miR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions.	Gastroenterology	2012	53
22552098	Sirolimus	Thoreen CC	A unifying model for mTORC1-mediated regulation of mRNA translation.	Nature	2012	370
22698676	Sirolimus	Mercier I	Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug.	The American journal of pathology	2012	68
22763451	Sirolimus	Tsai PT	Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice.	Nature	2012	176
22826320	Sirolimus	Amiel E	Inhibition of mechanistic target of rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice.	Journal of immunology	2012	40
22826565	Sirolimus	Zeng Z	Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.	Blood	2012	38
22859719	Sirolimus	Sun ZJ	Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.	Clinical cancer research 	2012	41
22907434	Sirolimus	Du W	ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer.	Oncogene	2013	27
22958934	Sirolimus	Kalaitzidis D	mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis.	Cell stem cell	2012	65
22981852	Sirolimus	Hinojosa CA	Enteric-delivered rapamycin enhances resistance of aged mice to pneumococcal pneumonia through reduced cellular senescence.	Experimental gerontology	2012	30
23117593	Sirolimus	Comas M	New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis.	Aging	2012	59
23123587	Sirolimus	Reith RM	Loss of Tsc2 in Purkinje cells is associated with autistic-like behavior in a mouse model of tuberous sclerosis complex.	Neurobiology of disease	2013	42
23123616	Sirolimus	Komarova EA	Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice.	Aging	2012	75
23152448	Sirolimus	Kaul A	Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner.	Genes & development	2012	33
23172145	Sirolimus	Gkogkas CG	Autism-related deficits via dysregulated eIF4E-dependent translational control.	Nature	2013	133
23173671	Sirolimus	Cui L	MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma.	BMC cancer	2012	31
23250422	Sirolimus	Sato A	Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex.	Nature communications	2012	36
23454836	Sirolimus	Livi CB	Rapamycin extends life span of Rb1+/- mice by inhibiting neuroendocrine tumors.	Aging	2013	37
23562079	Sirolimus	Chaveroux C	Molecular and genetic crosstalks between mTOR and ERRα are key determinants of rapamycin-induced nonalcoholic fatty liver.	Cell metabolism	2013	27
23863708	Sirolimus	Neff F	Rapamycin extends murine lifespan but has limited effects on aging.	The Journal of clinical investigation	2013	113
24014241	Sirolimus	Willems L	Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.	Blood	2013	56
24027431	Sirolimus	Kim JK	TBK1 regulates prostate cancer dormancy through mTOR inhibition.	Neoplasia	2013	26
24052624	Sirolimus	Wang Q	Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development.	Journal of the National Cancer Institute	2013	31
24092377	Sirolimus	Luo Y	Rapamycin enhances long-term hematopoietic reconstitution of ex vivo expanded mouse hematopoietic stem cells by inhibiting senescence.	Transplantation	2014	23
24231806	Sirolimus	Johnson SC	mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome.	Science	2013	86
24270418	Sirolimus	Liu SC	Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance.	The Journal of clinical investigation	2013	29
24282255	Sirolimus	Hasty P	eRapa restores a normal life span in a FAP mouse model.	Cancer prevention research	2014	20
24292708	Sirolimus	Berezhnoy A	Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity.	The Journal of clinical investigation	2014	43
24311635	Sirolimus	Kahn J	The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.	Neuro-oncology	2014	23
24409289	Sirolimus	Fok WC	Mice fed rapamycin have an increase in lifespan associated with major changes in the liver transcriptome.	PloS one	2014	43
24428799	Sirolimus	Schmeisser H	New function of type I IFN: induction of autophagy.	Journal of interferon & cytokine research 	2014	24
24469052	Sirolimus	Akeno N	p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.	Oncogene	2015	15
24556924	Sirolimus	Popovich IG	Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin.	Cancer biology & therapy	2014	25
24655348	Sirolimus	Leontieva OV	Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet.	Aging cell	2014	32
24671992	Sirolimus	Wahl SE	Mammalian target of rapamycin promotes oligodendrocyte differentiation, initiation and extent of CNS myelination.	The Journal of neuroscience 	2014	41
24671993	Sirolimus	Bercury KK	Conditional ablation of raptor or rictor has differential impact on oligodendrocyte differentiation and CNS myelination.	The Journal of neuroscience 	2014	33
24717934	Sirolimus	Morran DC	Targeting mTOR dependency in pancreatic cancer.	Gut	2014	25
24910242	Sirolimus	Umemura A	Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition.	Cell metabolism	2014	27
24931163	Sirolimus	Dodd KM	mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3.	Oncogene	2015	24
24973821	Sirolimus	Marçais A	The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells.	Nature immunology	2014	73
25015820	Sirolimus	Zhang L	Mammalian target of rapamycin complex 1 orchestrates invariant NKT cell differentiation and effector function.	Journal of immunology	2014	26
25082895	Sirolimus	Cornu M	Hepatic mTORC1 controls locomotor activity, body temperature, and lipid metabolism through FGF21.	Proceedings of the National Academy of Sciences of the United States of America	2014	34
25175012	Sirolimus	Zhu L	TSC1 controls macrophage polarization to prevent inflammatory disease.	Nature communications	2014	40
25307878	Sirolimus	Lee DH	Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.	International journal of cancer	2015	23
25383520	Sirolimus	Faller WJ	mTORC1-mediated translational elongation limits intestinal tumour initiation and growth.	Nature	2015	61
25450580	Sirolimus	Xu K	mTOR signaling in tumorigenesis.	Biochimica et biophysica acta	2014	34
25464856	Sirolimus	Staron MM	The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection.	Immunity	2014	66
25537496	Sirolimus	Martin SK	Brief report: the differential roles of mTORC1 and mTORC2 in mesenchymal stem cell differentiation.	Stem cells	2015	22
25601637	Sirolimus	Kong B	A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.	Gut	2016	14
25652038	Sirolimus	Schreiber KH	Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins.	Aging cell	2015	25
25798620	Sirolimus	Tanaka K	Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.	The Journal of clinical investigation	2015	35
25813405	Sirolimus	Wang Y	CRNDE, a long-noncoding RNA, promotes glioma cell growth and invasion through mTOR signaling.	Cancer letters	2015	45
26147250	Sirolimus	Laberge RM	MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation.	Nature cell biology	2015	103
26315673	Sirolimus	Hurez V	Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice.	Aging cell	2015	17
26476289	Sirolimus	Li L	Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans.	Journal of hepatology	2016	12
26565512	Sirolimus	Qiang L	Autophagy positively regulates DNA damage recognition by nucleotide excision repair.	Autophagy	2016	12
26695882	Sirolimus	Baar EL	Sex- and tissue-specific changes in mTOR signaling with age in C57BL/6J mice.	Aging cell	2016	19
26884601	Sirolimus	Viel S	TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway.	Science signaling	2016	24
26886608	Sirolimus	Xie R	Targeted Disruption of miR-17-92 Impairs Mouse Spermatogenesis by Activating mTOR Signaling Pathway.	Medicine	2016	11
27161823	Sirolimus	Gaubitz C	TORC2 Structure and Function.	Trends in biochemical sciences	2016	29
28162974	Sirolimus	Vila IK	A UBE2O-AMPKα2 Axis that Promotes Tumor Initiation and Progression Offers Opportunities for Therapy.	Cancer cell	2017	7
11034600	Ovalbumin	Kedl RM	T cells compete for access to antigen-bearing antigen-presenting cells.	The Journal of experimental medicine	2000	145
18297056	Ovalbumin	Yang L	Engineered lentivector targeting of dendritic cells for in vivo immunization.	Nature biotechnology	2008	87
20924102	Ovalbumin	Klages K	Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.	Cancer research	2010	73
22208977	Ovalbumin	Schaue D	Maximizing tumor immunity with fractionated radiation.	International journal of radiation oncology, biology, physics	2012	79
25687754	Ovalbumin	Evans CM	The polymeric mucin Muc5ac is required for allergic airway hyperreactivity.	Nature communications	2015	26
26560039	Ovalbumin	Lee JB	IL-25 and CD4(+) TH2 cells enhance type 2 innate lymphoid cell-derived IL-13 production, which promotes IgE-mediated experimental food allergy.	The Journal of allergy and clinical immunology	2016	19
26631690	Ovalbumin	Damo M	TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma.	Scientific reports	2015	17
27417020	Ovalbumin	Tordesillas L	Epicutaneous immunotherapy induces gastrointestinal LAP+ regulatory T cells and prevents food-induced anaphylaxis.	The Journal of allergy and clinical immunology	2017	8
11369200	afimoxifene	Arnold I	c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny.	Current biology 	2001	103
15084463	afimoxifene	Lo Celso C	Transient activation of beta-catenin signalling in adult mouse epidermis is sufficient to induce new hair follicles but continuous activation is required to maintain hair follicle tumours.	Development	2004	114
15601818	afimoxifene	McLean GW	Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression.	Genes & development	2004	89
15924142	afimoxifene	Christophorou MA	Temporal dissection of p53 function in vitro and in vivo.	Nature genetics	2005	78
21113150	afimoxifene	Jaskelioff M	Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice.	Nature	2011	200
21852537	afimoxifene	Garcia D	Validation of MdmX as a therapeutic target for reactivating p53 in tumors.	Genes & development	2011	36
10728691	Cyclooxygenase 2 Inhibitors	Masferrer JL	Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.	Cancer research	2000	178
15958566	Cyclooxygenase 2 Inhibitors	Sharma S	Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer.	Cancer research	2005	106
16186186	Cyclooxygenase 2 Inhibitors	Rodriguez PC	Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma.	The Journal of experimental medicine	2005	152
17483367	Cyclooxygenase 2 Inhibitors	Sinha P	Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells.	Cancer research	2007	212
19218449	Cyclooxygenase 2 Inhibitors	Hu M	Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast.	Proceedings of the National Academy of Sciences of the United States of America	2009	68
20124728	Cyclooxygenase 2 Inhibitors	Hirota Y	Uterine-specific p53 deficiency confers premature uterine senescence and promotes preterm birth in mice.	The Journal of clinical investigation	2010	65
21730361	Cyclooxygenase 2 Inhibitors	Nakanishi Y	COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps.	Carcinogenesis	2011	44
22641101	Cyclooxygenase 2 Inhibitors	Xin X	Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model.	Laboratory investigation; a journal of technical methods and pathology	2012	34
12907622	gemcitabine	Nowak AK	Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.	Cancer research	2003	94
14747554	gemcitabine	Feng WH	Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.	Journal of virology	2004	84
16166452	gemcitabine	Suzuki E	Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.	Clinical cancer research 	2005	255
17200371	gemcitabine	Korpanty G	Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature.	Clinical cancer research 	2007	75
17308067	gemcitabine	Senkal CE	Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas.	Molecular cancer therapeutics	2007	59
17332349	gemcitabine	Feldmann G	Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers.	Cancer research	2007	242
17404099	gemcitabine	Nomi T	Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.	Clinical cancer research 	2007	211
17440100	gemcitabine	Kunnumakkara AB	Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.	Cancer research	2007	145
17617589	gemcitabine	Sinha P	Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response.	Journal of immunology	2007	222
17671218	gemcitabine	Ko HJ	A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.	Cancer research	2007	62
18413796	gemcitabine	Melisi D	LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.	Molecular cancer therapeutics	2008	93
18772115	gemcitabine	Shaked Y	Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.	Cancer cell	2008	130
19336265	gemcitabine	Le HK	Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice.	International immunopharmacology	2009	89
19501590	gemcitabine	Mueller MT	Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.	Gastroenterology	2009	81
19908231	gemcitabine	Harikumar KB	Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer.	International journal of cancer	2010	52
20072652	gemcitabine	Lin L	A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.	Neoplasia	2010	54
20332237	gemcitabine	Dineen SP	Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer.	Cancer research	2010	43
20388795	gemcitabine	Vincent J	5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.	Cancer research	2010	206
20683663	gemcitabine	Du Z	Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells.	Digestive diseases and sciences	2011	54
21148071	gemcitabine	Dangi-Garimella S	Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.	Cancer research	2011	37
21408027	gemcitabine	Bao B	Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer.	PloS one	2011	73
21436454	gemcitabine	Beatty GL	CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.	Science	2011	405
21525939	gemcitabine	Donadelli M	Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism.	Cell death & disease	2011	45
21680779	gemcitabine	Mundy-Bosse BL	Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice.	Cancer research	2011	48
21742805	gemcitabine	Garrido-Laguna I	Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.	Clinical cancer research 	2011	58
21864475	gemcitabine	Li C	c-Met is a marker of pancreatic cancer stem cells and therapeutic target.	Gastroenterology	2011	119
21969517	gemcitabine	Von Hoff DD	Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.	Journal of clinical oncology 	2011	260
22585996	gemcitabine	Frese KK	nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.	Cancer discovery	2012	93
22653638	gemcitabine	Sumida K	Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses.	European journal of immunology	2012	33
22926062	gemcitabine	Tongu M	Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo.	Cancer immunology, immunotherapy 	2013	34
23202296	gemcitabine	Bruchard M	Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.	Nature medicine	2013	139
23222511	gemcitabine	Fokas E	Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.	Cell death & disease	2012	57
23348422	gemcitabine	Kozono S	Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells.	Cancer research	2013	26
23402593	gemcitabine	Lee GY	Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer.	ACS nano	2013	47
23520471	gemcitabine	Kreahling JM	Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas.	PloS one	2013	26
23593991	gemcitabine	Thompson R	The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design.	British journal of clinical pharmacology	2013	35
23626745	gemcitabine	Lesterhuis WJ	Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity.	PloS one	2013	31
23836645	gemcitabine	Neesse A	CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer.	Proceedings of the National Academy of Sciences of the United States of America	2013	48
23995783	gemcitabine	Weizman N	Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase.	Oncogene	2014	45
24143858	gemcitabine	Meng H	Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice.	ACS nano	2013	27
24148817	gemcitabine	Reid G	Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.	Annals of oncology 	2013	33
24780756	gemcitabine	Ding ZC	Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis.	Cancer research	2014	25
24856586	gemcitabine	Özdemir BC	Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival.	Cancer cell	2014	307
24859161	gemcitabine	Li L	Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.	Gastroenterology	2014	29
24919854	gemcitabine	Gelbert LM	Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.	Investigational new drugs	2014	57
25277192	gemcitabine	Khan S	MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer.	Oncotarget	2014	33
25402324	gemcitabine	Hiroshima Y	Efficacy of tumor-targeting Salmonella typhimurium A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX) and cell line mouse models.	Oncotarget	2014	53
25544770	gemcitabine	Zhao T	Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.	Oncotarget	2015	22
25776964	gemcitabine	Meng H	Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.	ACS nano	2015	26
25834145	gemcitabine	Duluc C	Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance.	EMBO molecular medicine	2015	20
25840985	gemcitabine	Khan S	Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer.	Cancer research	2015	19
25888329	gemcitabine	Beatty GL	Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages.	Gastroenterology	2015	33
25889214	gemcitabine	Li Z	The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.	Journal of translational medicine	2015	45
25934888	gemcitabine	Yen WC	Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency.	Clinical cancer research 	2015	42
26036346	gemcitabine	Tréhoux S	Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells.	Biochimica et biophysica acta	2015	20
26077591	gemcitabine	Miller BW	Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.	EMBO molecular medicine	2015	33
26169969	gemcitabine	Hidalgo M	SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial.	Clinical cancer research 	2015	30
26255562	gemcitabine	Nagathihalli NS	Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.	Gastroenterology	2015	16
26517239	gemcitabine	Vendetti FP	The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.	Oncotarget	2015	26
26560028	gemcitabine	Zheng X	Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.	Nature	2015	289
27003603	gemcitabine	Wörmann SM	Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.	Gastroenterology	2016	17
27049944	gemcitabine	Seifert L	The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression.	Nature	2016	29
27216178	gemcitabine	Schultz MJ	The Tumor-Associated Glycosyltransferase ST6Gal-I Regulates Stem Cell Transcription Factors and Confers a Cancer Stem Cell Phenotype.	Cancer research	2016	12
12453409	Reactive Oxygen Species	Ellisen LW	REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species.	Molecular cell	2002	131
14701813	Reactive Oxygen Species	Lin Y	Tumor necrosis factor-induced nonapoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation.	The Journal of biological chemistry	2004	122
14707072	Reactive Oxygen Species	Kusmartsev S	Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.	Journal of immunology	2004	220
15647368	Reactive Oxygen Species	Petros JA	mtDNA mutations increase tumorigenicity in prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2005	249
15811878	Reactive Oxygen Species	Komarova EA	p53 is a suppressor of inflammatory response in mice.	FASEB journal 	2005	70
16001073	Reactive Oxygen Species	Radisky DC	Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability.	Nature	2005	352
16847346	Reactive Oxygen Species	Kondratov RV	Early aging and age-related pathologies in mice deficient in BMAL1, the core componentof the circadian clock.	Genes & development	2006	272
17055439	Reactive Oxygen Species	St-Pierre J	Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators.	Cell	2006	567
18006848	Reactive Oxygen Species	Nefedova Y	Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells.	Cancer research	2007	79
18074631	Reactive Oxygen Species	Spiegelman BM	Transcriptional control of mitochondrial energy metabolism through the PGC1 coactivators.	Novartis Foundation symposium	2007	59
18216297	Reactive Oxygen Species	Wernig G	The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.	Blood	2008	50
18372916	Reactive Oxygen Species	Frohlich DA	The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis.	Oncogene	2008	58
18388260	Reactive Oxygen Species	Ishikawa K	ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis.	Science	2008	310
18394557	Reactive Oxygen Species	Duran A	The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis.	Cancer cell	2008	181
18413749	Reactive Oxygen Species	Derdak Z	The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells.	Cancer research	2008	56
18754859	Reactive Oxygen Species	Ono M	Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy.	Cancer science	2008	96
18832739	Reactive Oxygen Species	Youn JI	Subsets of myeloid-derived suppressor cells in tumor-bearing mice.	Journal of immunology	2008	503
19047182	Reactive Oxygen Species	Sung SY	Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis.	Cancer research	2008	56
19118006	Reactive Oxygen Species	Cano CE	Tumor protein 53-induced nuclear protein 1 is a major mediator of p53 antioxidant function.	Cancer research	2009	46
19190247	Reactive Oxygen Species	Lucas DM	The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.	Blood	2009	55
19208652	Reactive Oxygen Species	Park JS	A heteroplasmic, not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis via alteration in reactive oxygen species generation and apoptosis.	Human molecular genetics	2009	60
19369943	Reactive Oxygen Species	Cao J	Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity.	The EMBO journal	2009	92
19380816	Reactive Oxygen Species	Corzo CA	Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells.	Journal of immunology	2009	166
19413947	Reactive Oxygen Species	Lebedeva MA	Loss of p53 causes mitochondrial DNA depletion and altered mitochondrial reactive oxygen species homeostasis.	Biochimica et biophysica acta	2009	62
20160076	Reactive Oxygen Species	Alexander A	ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS.	Proceedings of the National Academy of Sciences of the United States of America	2010	181
20354168	Reactive Oxygen Species	Juntilla MM	AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species.	Blood	2010	82
20421486	Reactive Oxygen Species	Weinberg F	Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity.	Proceedings of the National Academy of Sciences of the United States of America	2010	375
20583212	Reactive Oxygen Species	Senturk S	Transforming growth factor-beta induces senescence in hepatocellular carcinoma cells and inhibits tumor growth.	Hepatology	2010	53
20663956	Reactive Oxygen Species	Li M	The ATM-p53 pathway suppresses aneuploidy-induced tumorigenesis.	Proceedings of the National Academy of Sciences of the United States of America	2010	71
21040902	Reactive Oxygen Species	Abbas HA	Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity.	Cell stem cell	2010	50
21300795	Reactive Oxygen Species	Kim MJ	Involvement of autophagy in oncogenic K-Ras-induced malignant cell transformation.	The Journal of biological chemistry	2011	76
21307849	Reactive Oxygen Species	Sahin E	Telomere dysfunction induces metabolic and mitochondrial compromise.	Nature	2011	324
21358671	Reactive Oxygen Species	Bell EL	SirT3 suppresses hypoxia inducible factor 1α and tumor growth by inhibiting mitochondrial ROS production.	Oncogene	2011	130
21555567	Reactive Oxygen Species	Shaw AT	Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress.	Proceedings of the National Academy of Sciences of the United States of America	2011	56
21853114	Reactive Oxygen Species	Hahm ER	Withaferin A-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species.	PloS one	2011	52
21983037	Reactive Oxygen Species	Suh YA	Multiple stress signals activate mutant p53 in vivo.	Cancer research	2011	35
22056359	Reactive Oxygen Species	Woo DK	Mitochondrial genome instability and ROS enhance intestinal tumorigenesis in APC(Min/+) mice.	The American journal of pathology	2012	37
22079466	Reactive Oxygen Species	Piao LS	CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma.	Cancer letters	2012	53
22144182	Reactive Oxygen Species	Valentin-Vega YA	Mitochondrial dysfunction in ataxia-telangiectasia.	Blood	2012	95
22341444	Reactive Oxygen Species	Raimundo N	Mitochondrial stress engages E2F1 apoptotic signaling to cause deafness.	Cell	2012	58
22750447	Reactive Oxygen Species	Zhou J	Roles of thioredoxin binding protein (TXNIP) in oxidative stress, apoptosis and cancer.	Mitochondrion	2013	28
22797809	Reactive Oxygen Species	Okuno Y	Pathological neoangiogenesis depends on oxidative stress regulation by ATM.	Nature medicine	2012	44
22897481	Reactive Oxygen Species	Sheng SL	Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma.	The FEBS journal	2012	42
22917578	Reactive Oxygen Species	Frank M	Mitophagy is triggered by mild oxidative stress in a mitochondrial fission dependent manner.	Biochimica et biophysica acta	2012	90
23108410	Reactive Oxygen Species	Higgs MR	Hepatitis C virus-induced activation of β-catenin promotes c-Myc expression and a cascade of pro-carcinogenetic events.	Oncogene	2013	27
23159440	Reactive Oxygen Species	Sakai J	Reactive oxygen species-induced actin glutathionylation controls actin dynamics in neutrophils.	Immunity	2012	41
23828498	Reactive Oxygen Species	Markowitz J	Myeloid-derived suppressor cells in breast cancer.	Breast cancer research and treatment	2013	32
24019511	Reactive Oxygen Species	Zhang Q	Mitochondrial localized Stat3 promotes breast cancer growth via phosphorylation of serine 727.	The Journal of biological chemistry	2013	38
24095676	Reactive Oxygen Species	Rouault-Pierre K	HIF-2α protects human hematopoietic stem/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stress.	Cell stem cell	2013	32
24209622	Reactive Oxygen Species	Emerling BM	Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors.	Cell	2013	34
24509161	Reactive Oxygen Species	Crosas-Molist E	The NADPH oxidase NOX4 inhibits hepatocyte proliferation and liver cancer progression.	Free radical biology & medicine	2014	20
24525732	Reactive Oxygen Species	Kang SU	Nonthermal plasma induces head and neck cancer cell death: the potential involvement of mitogen-activated protein kinase-dependent mitochondrial reactive oxygen species.	Cell death & disease	2014	33
24583638	Reactive Oxygen Species	Ogrunc M	Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation.	Cell death and differentiation	2014	46
24811539	Reactive Oxygen Species	Cichon MA	ROS-induced epithelial-mesenchymal transition in mammary epithelial cells is mediated by NF-kB-dependent activation of Snail.	Oncotarget	2014	40
24836575	Reactive Oxygen Species	Schwab L	Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage.	Nature medicine	2014	30
25079327	Reactive Oxygen Species	Santos MA	DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier.	Nature	2014	40
25378412	Reactive Oxygen Species	Usui F	Inflammasome activation by mitochondrial oxidative stress in macrophages leads to the development of angiotensin II-induced aortic aneurysm.	Arteriosclerosis, thrombosis, and vascular biology	2015	20
25833396	Reactive Oxygen Species	Schlie K	Survival of effector CD8+ T cells during influenza infection is dependent on autophagy.	Journal of immunology	2015	17
25883318	Reactive Oxygen Species	Okoye I	T cell metabolism. The protein LEM promotes CD8⁺ T cell immunity through effects on mitochondrial respiration.	Science	2015	22
25916556	Reactive Oxygen Species	Qiao S	A REDD1/TXNIP pro-oxidant complex regulates ATG4B activity to control stress-induced autophagy and sustain exercise capacity.	Nature communications	2015	31
25982278	Reactive Oxygen Species	Hubackova S	IFNγ induces oxidative stress, DNA damage and tumor cell senescence via TGFβ/SMAD signaling-dependent induction of Nox4 and suppression of ANT2.	Oncogene	2016	12
26095252	Reactive Oxygen Species	Truitt ML	Differential Requirements for eIF4E Dose in Normal Development and Cancer.	Cell	2015	41
26099526	Reactive Oxygen Species	Xu MJ	Fat-Specific Protein 27/CIDEC Promotes Development of Alcoholic Steatohepatitis in Mice and Humans.	Gastroenterology	2015	23
26308771	Reactive Oxygen Species	Jayavelu AK	NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells.	Leukemia	2016	11
26463424	Reactive Oxygen Species	Canli Ö	Glutathione peroxidase 4 prevents necroptosis in mouse erythroid precursors.	Blood	2016	13
26675351	Reactive Oxygen Species	Vinchi F	Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease.	Blood	2016	27
26934227	Reactive Oxygen Species	Ma C	NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.	Nature	2016	37
27918563	Reactive Oxygen Species	Himburg HA	Dickkopf-1 promotes hematopoietic regeneration via direct and niche-mediated mechanisms.	Nature medicine	2017	6
28273069	Reactive Oxygen Species	Rodríguez-Colman MJ	Interplay between metabolic identities in the intestinal crypt supports stem cell function.	Nature	2017	13
28479188	Reactive Oxygen Species	Cabezas-Wallscheid N	Vitamin A-Retinoic Acid Signaling Regulates Hematopoietic Stem Cell Dormancy.	Cell	2017	8
8945475	Cyclic AMP	Sicinski P	Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis.	Nature	1996	160
11557972	Cyclic AMP	Yoon JC	Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1.	Nature	2001	492
15930266	Cyclic AMP	Kirschner LS	A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues.	Cancer research	2005	75
18689544	Cyclic AMP	Arnold J	Human T-cell leukemia virus type-1 antisense-encoded gene, Hbz, promotes T-lymphocyte proliferation.	Blood	2008	80
21124456	Cyclic AMP	Gan B	Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells.	Nature	2010	141
21187332	Cyclic AMP	Paul PK	Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice.	The Journal of cell biology	2010	68
21400503	Cyclic AMP	Benetatos L	MEG3 imprinted gene contribution in tumorigenesis.	International journal of cancer	2011	62
22796012	Cyclic AMP	Wu J	Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human.	Cell	2012	614
23123854	Cyclic AMP	Mitra D	An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background.	Nature	2012	86
23706743	Cyclic AMP	Leprivier G	The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation.	Cell	2013	88
11069615	Doxycycline	Diamond I	Conditional gene expression in the epidermis of transgenic mice using the tetracycline-regulated transactivators tTA and rTA linked to the keratin 5 promoter.	The Journal of investigative dermatology	2000	94
11751631	Doxycycline	Fisher GH	Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes.	Genes & development	2001	193
12498714	Doxycycline	Moody SE	Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis.	Cancer cell	2002	114
15882627	Doxycycline	Hochedlinger K	Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues.	Cell	2005	292
16954387	Doxycycline	Sharma VM	Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc.	Molecular and cellular biology	2006	103
17450133	Doxycycline	Sarkisian CJ	Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis.	Nature cell biology	2007	153
18371448	Doxycycline	Stadtfeld M	Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse.	Cell stem cell	2008	284
19898465	Doxycycline	Guo X	TAp63 induces senescence and suppresses tumorigenesis in vivo.	Nature cell biology	2009	98
21293062	Doxycycline	Hiramatsu K	Generation of hyaline cartilaginous tissue from mouse adult dermal fibroblast culture by defined factors.	The Journal of clinical investigation	2011	44
21750654	Doxycycline	Yori JL	Krüppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer.	Neoplasia	2011	46
22105174	Doxycycline	Chakravarty D	Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.	The Journal of clinical investigation	2011	67
22158040	Doxycycline	Hsu TI	Sp1 expression regulates lung tumor progression.	Oncogene	2012	37
22908324	Doxycycline	Reis M	Endothelial Wnt/β-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression.	The Journal of experimental medicine	2012	35
25965570	Doxycycline	Shirai CL	Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo.	Cancer cell	2015	34
26091037	Doxycycline	Dow LE	Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer.	Cell	2015	80
9501205	trichostatin A	Richon VM	A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.	Proceedings of the National Academy of Sciences of the United States of America	1998	134
10200307	trichostatin A	Saito A	A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.	Proceedings of the National Academy of Sciences of the United States of America	1999	111
11533236	trichostatin A	Amann JM	ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain.	Molecular and cellular biology	2001	94
16107691	trichostatin A	Ho JS	p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest.	Molecular and cellular biology	2005	89
18046553	trichostatin A	Khan AN	Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells.	Cancer immunology, immunotherapy 	2008	51
18940731	trichostatin A	Hayashi K	Dynamic equilibrium and heterogeneity of mouse pluripotent stem cells with distinct functional and epigenetic states.	Cell stem cell	2008	215
20036643	trichostatin A	Benny Klimek ME	Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.	Biochemical and biophysical research communications	2010	57
20062804	trichostatin A	Yu S	Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice.	PloS one	2010	64
22038994	trichostatin A	Landreville S	Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.	Clinical cancer research 	2012	66
22419664	trichostatin A	Coulouarn C	Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma.	Cancer research	2012	46
22641068	trichostatin A	Buurman R	Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.	Gastroenterology	2012	52
22699621	trichostatin A	Pérez-Mancera PA	The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma.	Nature	2012	101
23379261	trichostatin A	Li Y	Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.	Molecular cancer	2013	37
23979134	trichostatin A	Yang Z	MicroRNA-433 inhibits liver cancer cell migration by repressing the protein expression and function of cAMP response element-binding protein.	The Journal of biological chemistry	2013	29
16221865	Histone Deacetylase Inhibitors	Bolger TA	Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death.	The Journal of neuroscience 	2005	68
18354397	Histone Deacetylase Inhibitors	Hajkova P	Chromatin dynamics during epigenetic reprogramming in the mouse germ line.	Nature	2008	177
18794144	Histone Deacetylase Inhibitors	Lee YS	The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis.	Cancer research	2008	78
20959362	Histone Deacetylase Inhibitors	Huang PH	Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases.	Molecular pharmacology	2011	40
22605338	Histone Deacetylase Inhibitors	Wang Y	Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity.	The Journal of biological chemistry	2012	49
23063601	Histone Deacetylase Inhibitors	Sung YM	Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease.	Experimental neurology	2013	26
23440245	Histone Deacetylase Inhibitors	Santoro F	A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance.	Blood	2013	39
24979794	Histone Deacetylase Inhibitors	Bhadury J	BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma.	Proceedings of the National Academy of Sciences of the United States of America	2014	34
26297712	Histone Deacetylase Inhibitors	Woods DM	HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.	Cancer immunology research	2015	23
26831668	Histone Deacetylase Inhibitors	Zhijun H	Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.	Tumour biology 	2016	11
10395330	9,10-Dimethyl-1,2-benzanthracene	Moore RJ	Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis.	Nature medicine	1999	181
12075356	9,10-Dimethyl-1,2-benzanthracene	Malliri A	Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours.	Nature	2002	94
12192050	9,10-Dimethyl-1,2-benzanthracene	Hirao A	Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner.	Molecular and cellular biology	2002	103
16024603	9,10-Dimethyl-1,2-benzanthracene	Jansen AP	Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis.	Cancer research	2005	68
17254968	9,10-Dimethyl-1,2-benzanthracene	Sun P	PRAK is essential for ras-induced senescence and tumor suppression.	Cell	2007	111
18208974	9,10-Dimethyl-1,2-benzanthracene	Gebhardt C	RAGE signaling sustains inflammation and promotes tumor development.	The Journal of experimental medicine	2008	113
21646541	9,10-Dimethyl-1,2-benzanthracene	Ma X	Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis.	Proceedings of the National Academy of Sciences of the United States of America	2011	65
21779166	9,10-Dimethyl-1,2-benzanthracene	Viarisio D	E6 and E7 from beta HPV38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice.	PLoS pathogens	2011	39
23699408	9,10-Dimethyl-1,2-benzanthracene	Inoue S	Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15.	Genes & development	2013	35
26168291	9,10-Dimethyl-1,2-benzanthracene	Nassar D	Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma.	Nature medicine	2015	34
10395322	Cancer Vaccines	Diehl L	CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy.	Nature medicine	1999	99
10395323	Cancer Vaccines	Sotomayor EM	Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40.	Nature medicine	1999	103
10866317	Cancer Vaccines	Mach N	Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.	Cancer research	2000	120
12682289	Cancer Vaccines	Hodi FS	Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.	Proceedings of the National Academy of Sciences of the United States of America	2003	194
12907617	Cancer Vaccines	Kusmartsev S	All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination.	Cancer research	2003	126
16824130	Cancer Vaccines	Klebanoff CA	CD8+ T-cell memory in tumor immunology and immunotherapy.	Immunological reviews	2006	150
19738077	Cancer Vaccines	Curran MA	Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors.	Cancer research	2009	49
21074057	Cancer Vaccines	Weber J	Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.	Seminars in oncology	2010	77
21150709	Cancer Vaccines	Fotin-Mleczek M	Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.	Journal of immunotherapy	2011	51
21242526	Cancer Vaccines	Chen T	Chemokine-containing exosomes are released from heat-stressed tumor cells via lipid raft-dependent pathway and act as efficient tumor vaccine.	Journal of immunology	2011	41
21908423	Cancer Vaccines	Pere H	A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens.	Blood	2011	48
23455713	Cancer Vaccines	Hailemichael Y	Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion.	Nature medicine	2013	97
23633484	Cancer Vaccines	Duraiswamy J	Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.	Cancer research	2013	152
24728077	Cancer Vaccines	Karyampudi L	Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody.	Cancer research	2014	30
24812273	Cancer Vaccines	Fu J	Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors.	Cancer research	2014	34
26669718	Cancer Vaccines	Ali OA	Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication.	Cancer immunology research	2016	13
27020860	Cancer Vaccines	Ahrends T	CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.	Cancer research	2016	13
17875725	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	Lyu YL	Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.	Cancer research	2007	83
17911593	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	Tili E	Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock.	Journal of immunology	2007	418
19029980	arsenic trioxide	Nasr R	Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.	Nature medicine	2008	87
20624968	arsenic trioxide	Kim J	Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector.	Proceedings of the National Academy of Sciences of the United States of America	2010	80
21183792	arsenic trioxide	Beauchamp EM	Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway.	The Journal of clinical investigation	2011	74
23291299	arsenic trioxide	Kim J	Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.	Cancer cell	2013	82
24412926	arsenic trioxide	Ablain J	Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.	Nature medicine	2014	28
16606824	docetaxel	Farokhzad OC	Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2006	334
17606733	docetaxel	Marangoni E	A new model of patient tumor-derived breast cancer xenografts for preclinical assays.	Clinical cancer research 	2007	119
17626183	docetaxel	Rottenberg S	Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	71
17909051	docetaxel	Loberg RD	Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.	Cancer research	2007	91
18006843	docetaxel	Halder J	Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.	Cancer research	2007	69
18172275	docetaxel	Haass NK	The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.	Clinical cancer research 	2008	81
18314475	docetaxel	Merritt WM	Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.	Journal of the National Cancer Institute	2008	89
18519787	docetaxel	Garnett CT	Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement.	Clinical cancer research 	2008	61
18645028	docetaxel	Meng Y	Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.	Molecular cancer therapeutics	2008	60
19147587	docetaxel	Kim RH	Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.	Cancer research	2009	73
19826044	docetaxel	Gan L	Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.	Cancer research	2009	52
20702612	docetaxel	Kodumudi KN	A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers.	Clinical cancer research 	2010	94
21768359	docetaxel	Oakes SR	Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737.	Proceedings of the National Academy of Sciences of the United States of America	2012	50
22139708	docetaxel	Feng B	MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3.	Cancer	2012	38
22359577	docetaxel	Dubrovska A	CXCR4 expression in prostate cancer progenitor cells.	PloS one	2012	38
22425996	docetaxel	Chen Z	A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.	Nature	2012	141
22491949	docetaxel	Hrkach J	Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.	Science translational medicine	2012	221
22952424	docetaxel	Domanska UM	CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.	Neoplasia	2012	39
23100512	docetaxel	Kodumudi KN	Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.	Journal of immunology	2012	33
23340294	docetaxel	Schott AF	Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.	Clinical cancer research 	2013	44
23589177	docetaxel	Vrignaud P	Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.	Clinical cancer research 	2013	26
24695093	docetaxel	Yang ZZ	Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas.	Biomaterials	2014	21
24985346	docetaxel	Ono M	Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells.	Science signaling	2014	105
24996221	docetaxel	Pan B	HMGB1-mediated autophagy promotes docetaxel resistance in human lung adenocarcinoma.	Molecular cancer	2014	24
25156255	docetaxel	Di Mitri D	Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer.	Nature	2014	42
25484141	docetaxel	van Soest RJ	Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.	European urology	2015	22
26153498	docetaxel	Maia AR	Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.	Annals of oncology 	2015	17
26859684	docetaxel	Black M	Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.	Oncotarget	2016	19
14611673	Azoxymethane	Tanaka T	A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate.	Cancer science	2003	179
16880406	Azoxymethane	Myung SJ	15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis.	Proceedings of the National Academy of Sciences of the United States of America	2006	89
17398123	Azoxymethane	Xiao H	The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis.	Immunity	2007	103
17408638	Azoxymethane	Yoshida Y	The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer.	Gastroenterology	2007	68
17631644	Azoxymethane	Osburn WO	Increased colonic inflammatory injury and formation of aberrant crypt foci in Nrf2-deficient mice upon dextran sulfate treatment.	International journal of cancer	2007	65
17681179	Azoxymethane	Li P	Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity.	Gastroenterology	2007	59
18054559	Azoxymethane	Fukata M	Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors.	Gastroenterology	2007	179
18219394	Azoxymethane	Popivanova BK	Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis.	The Journal of clinical investigation	2008	261
18981289	Azoxymethane	Maran RR	Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development.	The Journal of pharmacology and experimental therapeutics	2009	59
19138955	Azoxymethane	Khor TO	Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer.	Cancer prevention research	2008	83
19229991	Azoxymethane	Fukata M	Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors.	Inflammatory bowel diseases	2009	50
19328876	Azoxymethane	Lin S	The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer.	Gastroenterology	2009	48
19551144	Azoxymethane	Uronis JM	Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility.	PloS one	2009	124
19773434	Azoxymethane	Popivanova BK	Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice.	Cancer research	2009	61
20226691	Azoxymethane	Dupaul-Chicoine J	Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases.	Immunity	2010	150
20385749	Azoxymethane	Allen IC	The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer.	The Journal of experimental medicine	2010	180
20564343	Azoxymethane	Hosono K	Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase.	Molecular carcinogenesis	2010	59
20624890	Azoxymethane	Salcedo R	MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18.	The Journal of experimental medicine	2010	122
20855874	Azoxymethane	Zaki MH	IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation.	Journal of immunology	2010	76
21653642	Azoxymethane	Zhu H	EGFR signals downregulate tumor suppressors miR-143 and miR-145 in Western diet-promoted murine colon cancer: role of G1 regulators.	Molecular cancer research 	2011	42
21674704	Azoxymethane	Fukata M	Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis.	Inflammatory bowel diseases	2011	48
21987656	Azoxymethane	Stolfi C	Involvement of interleukin-21 in the regulation of colitis-associated colon cancer.	The Journal of experimental medicine	2011	36
22677195	Azoxymethane	Flores MBS	RETRACTED: Obesity-induced increase in tumor necrosis factor-α leads to development of colon cancer in mice.	Gastroenterology	2012	35
23027128	Azoxymethane	Zheng Y	Protein tyrosine kinase 6 protects cells from anoikis by directly phosphorylating focal adhesion kinase and activating AKT.	Oncogene	2013	25
23041326	Azoxymethane	Asfaha S	Mice that express human interleukin-8 have increased mobilization of immature myeloid cells, which exacerbates inflammation and accelerates colon carcinogenesis.	Gastroenterology	2013	37
23272179	Azoxymethane	Shang K	Crucial involvement of tumor-associated neutrophils in the regulation of chronic colitis-associated carcinogenesis in mice.	PloS one	2012	36
23669411	Azoxymethane	Thaker AI	IDO1 metabolites activate β-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice.	Gastroenterology	2013	27
23878224	Azoxymethane	Bosurgi L	Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer.	Proceedings of the National Academy of Sciences of the United States of America	2013	38
25994220	Azoxymethane	Shi C	Novel evidence for an oncogenic role of microRNA-21 in colitis-associated colorectal cancer.	Gut	2016	20
26055138	Azoxymethane	Polytarchou C	MicroRNA214 Is Associated With Progression of Ulcerative Colitis, and Inhibition Reduces Development of Colitis and Colitis-Associated Cancer in Mice.	Gastroenterology	2015	23
27876571	Azoxymethane	Yang Y	Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21.	Gastroenterology	2017	18
16952555	Dextran Sulfate	Fukata M	Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine.	Gastroenterology	2006	119
17178849	Dextran Sulfate	Khor TO	Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis.	Cancer research	2006	117
17723178	Dextran Sulfate	Clapper ML	Dextran sulfate sodium-induced colitis-associated neoplasia: a promising model for the development of chemopreventive interventions.	Acta pharmacologica Sinica	2007	59
18058233	Dextran Sulfate	Maines LW	Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase.	Digestive diseases and sciences	2008	57
18439915	Dextran Sulfate	Shah YM	Hypoxia-inducible factor augments experimental colitis through an MIF-dependent inflammatory signaling cascade.	Gastroenterology	2008	64
18521188	Dextran Sulfate	Meira LB	DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice.	The Journal of clinical investigation	2008	152
20603312	Dextran Sulfate	Chalaris A	Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice.	The Journal of experimental medicine	2010	65
20805871	Dextran Sulfate	Johansson ME	Bacteria penetrate the inner mucus layer before inflammation in the dextran sulfate colitis model.	PloS one	2010	82
21440550	Dextran Sulfate	Koch S	The Wnt antagonist Dkk1 regulates intestinal epithelial homeostasis and wound repair.	Gastroenterology	2011	40
21490394	Dextran Sulfate	Qiu W	PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice.	The Journal of clinical investigation	2011	48
23619146	Dextran Sulfate	Su L	TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis.	Gastroenterology	2013	55
23680148	Dextran Sulfate	Cooks T	Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer.	Cancer cell	2013	95
23752315	Dextran Sulfate	Ju S	Grape exosome-like nanoparticles induce intestinal stem cells and protect mice from DSS-induced colitis.	Molecular therapy 	2013	34
10221914	O-(chloroacetylcarbamoyl)fumagillol	Bergers G	Effects of angiogenesis inhibitors on multistage carcinogenesis in mice.	Science	1999	166
10766175	O-(chloroacetylcarbamoyl)fumagillol	Browder T	Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.	Cancer research	2000	276
24715464	O-(chloroacetylcarbamoyl)fumagillol	Korn C	Endothelial cell-derived non-canonical Wnt ligands control vascular pruning in angiogenesis.	Development	2014	23
18006825	Metformin	Dowling RJ	Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.	Cancer research	2007	269
18256928	Metformin	Phoenix KN	Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model.	Breast cancer research and treatment	2009	47
18469156	Metformin	Algire C	Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth.	Endocrine-related cancer	2008	64
18728386	Metformin	Anisimov VN	Metformin slows down aging and extends life span of female SHR mice.	Cell cycle	2008	82
18803638	Metformin	Tomimoto A	Metformin suppresses intestinal polyp growth in ApcMin/+ mice.	Cancer science	2008	58
19440038	Metformin	Liu B	Metformin induces unique biological and molecular responses in triple negative breast cancer cells.	Cell cycle	2009	123
19679549	Metformin	Kisfalvi K	Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth.	Cancer research	2009	109
19874425	Metformin	Rattan R	Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner.	Journal of cellular and molecular medicine	2011	56
20668229	Metformin	Green AS	The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation.	Blood	2010	53
21102522	Metformin	Algire C	Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo.	Oncogene	2011	48
21220315	Metformin	Iliopoulos D	Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion.	Proceedings of the National Academy of Sciences of the United States of America	2011	186
21676631	Metformin	Liu J	Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft.	Urologic oncology	2013	28
21881601	Metformin	Tomic T	Metformin inhibits melanoma development through autophagy and apoptosis mechanisms.	Cell death & disease	2011	75
22467080	Metformin	Bhalla K	Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis.	Cancer prevention research	2012	41
22500211	Metformin	Song CW	Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells.	Scientific reports	2012	70
22565037	Metformin	Cufi S	Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.	Oncotarget	2012	67
22576211	Metformin	Martin MJ	Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A.	Cancer discovery	2012	36
22643892	Metformin	Blandino G	Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC.	Nature communications	2012	52
23287468	Metformin	Vazquez-Martin A	The mitochondrial H(+)-ATP synthase and the lipogenic switch: new core components of metabolic reprogramming in induced pluripotent stem (iPS) cells.	Cell cycle	2013	29
23632475	Metformin	Storozhuk Y	Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK.	British journal of cancer	2013	58
23741061	Metformin	Cerezo M	Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner.	Molecular cancer therapeutics	2013	42
24322659	Metformin	Zhu P	Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.	Cancer prevention research	2014	24
24419232	Metformin	Dallaglio K	Paradoxic effects of metformin on endothelial cells and angiogenesis.	Carcinogenesis	2014	26
24474794	Metformin	Liu X	Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK.	Proceedings of the National Academy of Sciences of the United States of America	2014	68
24716225	Metformin	Koh SJ	Anti-inflammatory mechanism of metformin and its effects in intestinal inflammation and colitis-associated colon cancer.	Journal of gastroenterology and hepatology	2014	21
24957076	Metformin	Fuentes-Mattei E	Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer.	Journal of the National Cancer Institute	2014	32
24970804	Metformin	Tebbe C	Metformin limits the adipocyte tumor-promoting effect on ovarian cancer.	Oncotarget	2014	23
25196138	Metformin	Orecchioni S	The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells.	International journal of cancer	2015	30
25446664	Metformin	Lengyel E	Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.	American journal of obstetrics and gynecology	2015	21
25456211	Metformin	Han G	AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell.	Cancer biology & therapy	2015	19
25576058	Metformin	Cifarelli V	Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms.	Diabetes	2015	21
25624476	Metformin	Eikawa S	Immune-mediated antitumor effect by type 2 diabetes drug, metformin.	Proceedings of the National Academy of Sciences of the United States of America	2015	57
25875801	Metformin	Tan XL	Metformin suppresses pancreatic tumor growth with inhibition of NFκB/STAT3 inflammatory signaling.	Pancreas	2015	17
25940306	Metformin	O'Brien AJ	Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis.	The Biochemical journal	2015	17
26641266	Metformin	Incio J	Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages.	PloS one	2015	23
28089566	Metformin	Howell JJ	Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex.	Cell metabolism	2017	14
10190903	Galactosylceramides	Kitamura H	The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.	The Journal of experimental medicine	1999	163
10684858	Galactosylceramides	Smyth MJ	Differential tumor surveillance by natural killer (NK) and NKT cells.	The Journal of experimental medicine	2000	177
11257133	Galactosylceramides	Smyth MJ	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis.	The Journal of experimental medicine	2001	92
11830474	Galactosylceramides	Smyth MJ	Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide.	Blood	2002	109
12093876	Galactosylceramides	Crowe NY	A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas.	The Journal of experimental medicine	2002	102
12154358	Galactosylceramides	Fujii S	Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.	Nature immunology	2002	151
14657217	Galactosylceramides	Schmieg J	Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide.	The Journal of experimental medicine	2003	115
15711562	Galactosylceramides	Nichols KE	Regulation of NKT cell development by SAP, the protein defective in XLP.	Nature medicine	2005	124
16138194	Galactosylceramides	Parekh VV	Glycolipid antigen induces long-term natural killer T cell anergy in mice.	The Journal of clinical investigation	2005	146
21552205	Galactosylceramides	Aspeslagh S	Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis.	The EMBO journal	2011	47
24412610	Galactosylceramides	Arora P	A single subset of dendritic cells controls the cytokine bias of natural killer T cell responses to diverse glycolipid antigens.	Immunity	2014	32
24913977	Galactosylceramides	Macho-Fernandez E	Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.	Journal of immunology	2014	23
11085525	decitabine	Plumb JA	Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.	Cancer research	2000	96
16491118	decitabine	Aguilera O	Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer.	Oncogene	2006	93
18577219	decitabine	Silber J	miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells.	BMC medicine	2008	301
18577749	decitabine	Fujita T	CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas.	Journal of the National Cancer Institute	2008	62
19308264	decitabine	Garzia L	MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma.	PloS one	2009	79
20348135	decitabine	Patel K	Targeting of 5-aza-2'-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme.	Nucleic acids research	2010	43
21772049	decitabine	Kalac M	HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.	Blood	2011	37
22002305	decitabine	Ramachandran I	Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo.	Oncogene	2012	35
22237753	decitabine	Sun CY	Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation.	Kidney international	2012	35
22461695	decitabine	Yang D	Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo.	Journal of immunology	2012	30
23079745	decitabine	Kim JK	Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b.	Hepatology	2013	68
23236145	decitabine	Leonova KI	p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs.	Proceedings of the National Academy of Sciences of the United States of America	2013	72
23318422	decitabine	Xiang Y	MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.	Oncogene	2014	49
23493348	decitabine	Huang X	Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.	Clinical cancer research 	2013	44
23707781	decitabine	Letouzé E	SDH mutations establish a hypermethylator phenotype in paraganglioma.	Cancer cell	2013	119
23856509	decitabine	Koukos G	MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis.	Gastroenterology	2013	51
25224413	decitabine	Bejar R	TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.	Blood	2014	76
25445694	decitabine	Li SY	Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.	Journal of controlled release 	2015	20
25477340	decitabine	Takeshima H	Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.	Carcinogenesis	2015	18
27623509	decitabine	Lucarini V	Combining Type I Interferons and 5-Aza-2'-Deoxycitidine to Improve Anti-Tumor Response against Melanoma.	The Journal of investigative dermatology	2017	7
10477735	bisbenzimide ethoxide trihydrochloride	Holyoake T	Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia.	Blood	1999	106
11493466	bisbenzimide ethoxide trihydrochloride	Wulf GG	A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia.	Blood	2001	87
11801536	bisbenzimide ethoxide trihydrochloride	Kim M	The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.	Clinical cancer research 	2002	95
16849428	bisbenzimide ethoxide trihydrochloride	Szotek PP	Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness.	Proceedings of the National Academy of Sciences of the United States of America	2006	229
18680391	bisbenzimide ethoxide trihydrochloride	Huang D	Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines.	Stem cells and development	2009	48
19318631	bisbenzimide ethoxide trihydrochloride	Migita T	Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.	Journal of the National Cancer Institute	2009	103
19464919	bisbenzimide ethoxide trihydrochloride	Tirino V	The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer.	European journal of cardio-thoracic surgery 	2009	71
20019840	bisbenzimide ethoxide trihydrochloride	Vesuna F	Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression.	Neoplasia	2009	66
20354527	bisbenzimide ethoxide trihydrochloride	Hu L	Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant.	British journal of cancer	2010	82
21468047	bisbenzimide ethoxide trihydrochloride	Xiang R	Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer.	British journal of cancer	2011	59
22284662	bisbenzimide ethoxide trihydrochloride	López J	Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance.	BMC cancer	2012	44
23009336	bisbenzimide ethoxide trihydrochloride	Singh S	EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer.	Molecular cancer	2012	69
26752044	bisbenzimide ethoxide trihydrochloride	Morata-Tarifa C	Low adherent cancer cell subpopulations are enriched in tumorigenic and metastatic epithelial-to-mesenchymal transition-induced cancer stem-like cells.	Scientific reports	2016	10
11861387	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Hu L	Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.	Cancer research	2002	85
15059890	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Stiff T	ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation.	Cancer research	2004	300
16622124	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Yaguchi S	Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.	Journal of the National Cancer Institute	2006	70
19435898	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Mukherjee B	EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma.	Cancer research	2009	74
20145128	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Ward CS	Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy.	Cancer research	2010	66
22252008	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Maycotte P	Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy.	Autophagy	2012	86
23604117	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Zhu X	Synergy between Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6 and HIV-1 Nef protein in promotion of angiogenesis and oncogenesis: role of the AKT signaling pathway.	Oncogene	2014	21
24194905	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Chai ZT	MicroRNA-26a inhibits angiogenesis by down-regulating VEGFA through the PIK3C2α/Akt/HIF-1α pathway in hepatocellular carcinoma.	PloS one	2013	29
24892425	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	Forget MA	Macrophage colony-stimulating factor augments Tie2-expressing monocyte differentiation, angiogenic function, and recruitment in a mouse model of breast cancer.	PloS one	2014	23
14709739	temozolomide	Calabrese CR	Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.	Journal of the National Cancer Institute	2004	108
17196391	temozolomide	Clement V	HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity.	Current biology 	2007	303
17363489	temozolomide	Thomas HD	Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.	Molecular cancer therapeutics	2007	64
17473206	temozolomide	Donawho CK	ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.	Clinical cancer research 	2007	210
18952979	temozolomide	Kitange GJ	Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.	Neuro-oncology	2009	47
19143470	temozolomide	Curtin JF	HMGB1 mediates endogenous TLR2 activation and brain tumor regression.	PLoS medicine	2009	128
19147766	temozolomide	Russo AL	In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.	Clinical cancer research 	2009	47
19265662	temozolomide	Bleau AM	PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.	Cell stem cell	2009	239
20530668	temozolomide	McEllin B	PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.	Cancer research	2010	81
21116835	temozolomide	Zhu X	Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.	Journal of neuro-oncology	2011	39
21317208	temozolomide	Prasad G	Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.	Neuro-oncology	2011	48
21768296	temozolomide	Mitchell DA	Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.	Blood	2011	45
21948969	temozolomide	Hong M	Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control.	Cancer research	2011	57
22156195	temozolomide	Agnihotri S	Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.	The Journal of clinical investigation	2012	32
22173583	temozolomide	Kanai R	Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.	Journal of the National Cancer Institute	2012	36
22984531	temozolomide	Safdie F	Fasting enhances the response of glioma to chemo- and radiotherapy.	PloS one	2012	33
23132831	temozolomide	Yuan S	Effective elimination of cancer stem cells by a novel drug combination strategy.	Stem cells	2013	31
24608791	temozolomide	Auffinger B	Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy.	Cell death and differentiation	2014	58
25437539	temozolomide	Stewart E	Targeting the DNA repair pathway in Ewing sarcoma.	Cell reports	2014	30
25867026	temozolomide	Sesen J	Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response.	PloS one	2015	25
26188279	temozolomide	Yu Z	NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.	Cancer letters	2015	19
26431379	temozolomide	Yu Z	Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.	Oncotarget	2015	22
27793847	temozolomide	Nagel ZD	DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme.	Cancer research	2017	8
16356836	resveratrol	Garvin S	Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo.	Cancer letters	2006	67
16873680	resveratrol	Zang M	Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice.	Diabetes	2006	167
18835033	resveratrol	Wang RH	Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice.	Cancer cell	2008	260
18851829	resveratrol	Wang RH	Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis.	Molecular cell	2008	116
19326431	resveratrol	Narayanan NK	Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice.	International journal of cancer	2009	60
19503100	resveratrol	Boily G	SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol.	Oncogene	2009	52
19897059	resveratrol	Baur JA	Biochemical effects of SIRT1 activators.	Biochimica et biophysica acta	2010	40
20332304	resveratrol	Cui X	Resveratrol suppresses colitis and colon cancer associated with colitis.	Cancer prevention research	2010	49
21304978	resveratrol	Shankar S	Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition.	PloS one	2011	79
23272133	resveratrol	Sheth S	Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway.	PloS one	2012	53
25533949	resveratrol	Sajish M	A human tRNA synthetase is a potent PARP1-activating effector target for resveratrol.	Nature	2015	22
25884904	resveratrol	Ji Q	Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.	BMC cancer	2015	28
25938543	resveratrol	Dai W	By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice.	Oncotarget	2015	24
26223300	resveratrol	Cai H	Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice.	Science translational medicine	2015	23
14971051	Oligodeoxyribonucleotides	Vollmer J	Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.	European journal of immunology	2004	108
18941113	Oligodeoxyribonucleotides	Houot R	T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy.	Blood	2009	54
11017141	sphingosine 1-phosphate	Morita Y	Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy.	Nature medicine	2000	100
12890694	sphingosine 1-phosphate	Pettus BJ	The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha.	FASEB journal 	2003	83
14522923	sphingosine 1-phosphate	French KJ	Discovery and evaluation of inhibitors of human sphingosine kinase.	Cancer research	2003	180
16530706	sphingosine 1-phosphate	Visentin B	Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages.	Cancer cell	2006	148
16632640	sphingosine 1-phosphate	French KJ	Antitumor activity of sphingosine kinase inhibitors.	The Journal of pharmacology and experimental therapeutics	2006	79
16980623	sphingosine 1-phosphate	Kohno M	Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation.	Molecular and cellular biology	2006	89
17090686	sphingosine 1-phosphate	Oskouian B	Sphingosine-1-phosphate lyase potentiates apoptosis via p53- and p38-dependent pathways and is down-regulated in colon cancer.	Proceedings of the National Academy of Sciences of the United States of America	2006	76
17548599	sphingosine 1-phosphate	Bai A	Kruppel-like factor 2 controls T cell trafficking by activating L-selectin (CD62L) and sphingosine-1-phosphate receptor 1 transcription.	Journal of immunology	2007	70
18824518	sphingosine 1-phosphate	Kawamori T	Role for sphingosine kinase 1 in colon carcinogenesis.	FASEB journal 	2009	86
21769103	sphingosine 1-phosphate	Kim CH	Conditioning for hematopoietic transplantation activates the complement cascade and induces a proteolytic environment in bone marrow: a novel role for bioactive lipids and soluble C5b-C9 as homing factors.	Leukemia	2012	49
22049516	sphingosine 1-phosphate	Juarez JG	Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by CXCR4 antagonists in mice.	Blood	2012	40
22298596	sphingosine 1-phosphate	Nagahashi M	Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis.	Cancer research	2012	90
22664872	sphingosine 1-phosphate	Nijnik A	The role of sphingosine-1-phosphate transporter Spns2 in immune system function.	Journal of immunology	2012	32
22707406	sphingosine 1-phosphate	Ponnusamy S	Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis.	EMBO molecular medicine	2012	41
22723910	sphingosine 1-phosphate	Hisano Y	Mouse SPNS2 functions as a sphingosine-1-phosphate transporter in vascular endothelial cells.	PloS one	2012	53
23143305	sphingosine 1-phosphate	Çuburu N	Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses.	The Journal of clinical investigation	2012	44
23273921	sphingosine 1-phosphate	Liang J	Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer.	Cancer cell	2013	151
23861887	sphingosine 1-phosphate	Rex K	Sphingosine kinase activity is not required for tumor cell viability.	PloS one	2013	26
24859201	sphingosine 1-phosphate	Hait NC	Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory.	Nature neuroscience	2014	37
25274307	sphingosine 1-phosphate	Muppidi JR	Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma.	Nature	2014	40
25347472	sphingosine 1-phosphate	Degagné E	Sphingosine-1-phosphate lyase downregulation promotes colon carcinogenesis through STAT3-activated microRNAs.	The Journal of clinical investigation	2014	34
25831442	sphingosine 1-phosphate	Proia RL	Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy.	The Journal of clinical investigation	2015	63
26082434	sphingosine 1-phosphate	Panneer Selvam S	Binding of the sphingolipid S1P to hTERT stabilizes telomerase at the nuclear periphery by allosterically mimicking protein phosphorylation.	Science signaling	2015	20
27956387	sphingosine 1-phosphate	Powell JA	Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.	Blood	2017	5
28052056	sphingosine 1-phosphate	van der Weyden L	Genome-wide in vivo screen identifies novel host regulators of metastatic colonization.	Nature	2017	19
10815932	oxaliplatin	Ciardiello F	Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.	Clinical cancer research 	2000	110
16847145	oxaliplatin	Holzer AK	Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.	Molecular pharmacology	2006	68
18996970	oxaliplatin	Larson CA	The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs.	Molecular pharmacology	2009	49
19383922	oxaliplatin	Kopetz S	Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.	Cancer research	2009	48
19881547	oxaliplatin	Tesniere A	Immunogenic death of colon cancer cells treated with oxaliplatin.	Oncogene	2010	142
20205720	oxaliplatin	Ta LE	Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice.	Molecular pain	2010	43
20951698	oxaliplatin	Lombardo Y	Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice.	Gastroenterology	2011	49
21383056	oxaliplatin	Ma Y	Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy.	The Journal of experimental medicine	2011	88
21743023	oxaliplatin	Melisi D	Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.	Journal of the National Cancer Institute	2011	41
21825039	oxaliplatin	Ding ZB	Autophagy activation in hepatocellular carcinoma contributes to the tolerance of oxaliplatin via reactive oxygen species modulation.	Clinical cancer research 	2011	38
22825584	oxaliplatin	Julien S	Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer.	Clinical cancer research 	2012	77
23461901	oxaliplatin	Selvakumaran M	Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy.	Clinical cancer research 	2013	41
23477783	oxaliplatin	Trevisan G	Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade.	Cancer research	2013	28
24440715	oxaliplatin	Minett MS	Pain without nociceptors? Nav1.7-independent pain mechanisms.	Cell reports	2014	32
24465408	oxaliplatin	Nangia-Makker P	Metformin: a potential therapeutic agent for recurrent colon cancer.	PloS one	2014	30
25616665	oxaliplatin	Zhang Y	MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer.	The Journal of biological chemistry	2015	22
25924065	oxaliplatin	Shalapour S	Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy.	Nature	2015	50
25943534	oxaliplatin	Stewart R	Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.	Cancer immunology research	2015	20
26872698	oxaliplatin	Pfirschke C	Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.	Immunity	2016	49
28125674	oxaliplatin	Makker PG	Characterisation of Immune and Neuroinflammatory Changes Associated with Chemotherapy-Induced Peripheral Neuropathy.	PloS one	2017	7
16166336	4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	Conaway CC	Phenethyl isothiocyanate and sulforaphane and their N-acetylcysteine conjugates inhibit malignant progression of lung adenomas induced by tobacco carcinogens in A/J mice.	Cancer research	2005	77
20810672	4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	Memmott RM	Metformin prevents tobacco carcinogen--induced lung tumorigenesis.	Cancer prevention research	2010	142
17616639	Immunotoxins	Litzinger MT	IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.	Blood	2007	70
18988862	Immunotoxins	Weldon JE	A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.	Blood	2009	55
20215554	Immunotoxins	Wayne AS	Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.	Clinical cancer research 	2010	57
25239937	Immunotoxins	Alewine C	Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers.	Molecular cancer therapeutics	2014	28
17981559	epigallocatechin gallate	Shankar S	EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer.	Frontiers in bioscience 	2008	56
21965273	epigallocatechin gallate	Wang H	Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1α.	Carcinogenesis	2011	45
25875356	epigallocatechin gallate	Pan H	Mitochondrial modulation by Epigallocatechin 3-Gallate ameliorates cisplatin induced renal injury through decreasing oxidative/nitrative stress, inflammation and NF-kB in mice.	PloS one	2015	15
16092118	Curcumin	Li L	Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis.	Cancer	2005	99
16243823	Curcumin	Aggarwal BB	Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice.	Clinical cancer research 	2005	105
17332326	Curcumin	Li M	Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway.	Cancer research	2007	70
17545551	Curcumin	Lin YG	Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.	Clinical cancer research 	2007	87
18339878	Curcumin	Subramaniam D	Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity.	Cancer research	2008	50
18381954	Curcumin	Kunnumakkara AB	Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products.	Clinical cancer research 	2008	64
18593936	Curcumin	Chadalapaka G	Curcumin decreases specificity protein expression in bladder cancer cells.	Cancer research	2008	57
19714451	Curcumin	Padhye S	Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice.	Pharmaceutical research	2009	49
20538607	Curcumin	Jutooru I	Inhibition of NFkappaB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation.	The Journal of biological chemistry	2010	66
20553984	Curcumin	Mohanty C	The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation.	Biomaterials	2010	55
21787756	Curcumin	Khor TO	Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of Nrf2 via promoter CpGs demethylation.	Biochemical pharmacology	2011	42
22030090	Curcumin	Tu SP	Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth.	Cancer prevention research	2012	40
23457487	Curcumin	Yu J	Curcumin down-regulates DNA methyltransferase 1 and plays an anti-leukemic role in acute myeloid leukemia.	PloS one	2013	31
23548270	Curcumin	Yu CC	miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer.	Cancer research	2013	40
23894315	Curcumin	Roy S	Difluorinated-curcumin (CDF) restores PTEN expression in colon cancer cells by down-regulating miR-21.	PloS one	2013	27
25653233	Curcumin	Toden S	Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer.	Carcinogenesis	2015	21
26116834	Curcumin	Taverna S	Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth: a possible role for exosomal disposal of miR-21.	Oncotarget	2015	15
7539101	pirinixic acid	Lee SS	Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators.	Molecular and cellular biology	1995	276
17438130	pirinixic acid	Shah YM	Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation.	Molecular and cellular biology	2007	79
17601491	pirinixic acid	Lundåsen T	PPARalpha is a key regulator of hepatic FGF21.	Biochemical and biophysical research communications	2007	99
18006136	pirinixic acid	Gonzalez FJ	PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators.	Toxicology	2008	72
11350913	Poly Adenosine Diphosphate Ribose	Sunwoo JB	Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.	Clinical cancer research 	2001	99
15829966	Poly Adenosine Diphosphate Ribose	Bryant HE	Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.	Nature	2005	1004
15833866	Poly Adenosine Diphosphate Ribose	Chinnaiyan P	Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).	Cancer research	2005	89
21706030	Poly Adenosine Diphosphate Ribose	Johnson N	Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.	Nature medicine	2011	69
22445484	Poly Adenosine Diphosphate Ribose	Bunting SF	BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair.	Molecular cell	2012	87
22869595	Poly Adenosine Diphosphate Ribose	Daniel JA	Loss of ATM kinase activity leads to embryonic lethality in mice.	The Journal of cell biology	2012	41
24842372	Poly Adenosine Diphosphate Ribose	Polato F	CtIP-mediated resection is essential for viability and can operate independently of BRCA1.	The Journal of experimental medicine	2014	26
24911143	Poly Adenosine Diphosphate Ribose	Tanaka M	Ewing's sarcoma precursors are highly enriched in embryonic osteochondrogenic progenitors.	The Journal of clinical investigation	2014	23
25629353	Poly Adenosine Diphosphate Ribose	Howard SM	DNA damage response factors from diverse pathways, including DNA crosslink repair, mediate alternative end joining.	PLoS genetics	2015	33
25642963	Poly Adenosine Diphosphate Ribose	Ceccaldi R	Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair.	Nature	2015	95
26100884	Poly Adenosine Diphosphate Ribose	Henneman L	Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2015	15
17562815	vadimezan	Roberts ZJ	The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis.	The Journal of experimental medicine	2007	61
23585680	vadimezan	Conlon J	Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.	Journal of immunology	2013	65
23910378	vadimezan	Gao P	Structure-function analysis of STING activation by cG(2',5')pA(3',5')p and targeting by antiviral DMXAA.	Cell	2013	76
25959818	vadimezan	Corrales L	Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.	Cell reports	2015	96
17909050	triptolide	Phillips PA	Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70.	Cancer research	2007	89
23076356	triptolide	Chugh R	A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer.	Science translational medicine	2012	63
25109336	triptolide	Sarkar TR	GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer.	Oncogene	2015	19
26447544	triptolide	Jiang QW	Synergistic anticancer effects of triptolide and celastrol, two main compounds from thunder god vine.	Oncotarget	2015	20
16651429	tripterine	Yang H	Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice.	Cancer research	2006	146
18202019	tripterine	Zhang T	A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells.	Molecular cancer therapeutics	2008	92
20160026	tripterine	Pang X	Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway.	Cancer research	2010	44
24667175	tripterine	Lee HW	Celastrol inhibits gastric cancer growth by induction of apoptosis and autophagy.	BMB reports	2014	26
25139619	tripterine	Fribley AM	Celastrol induces unfolded protein response-dependent cell death in head and neck cancer.	Experimental cell research	2015	15
25611379	tripterine	Li HY	Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells: an in vitro and in vivo study.	Cell death & disease	2015	33
26631113	tripterine	Uttarkar S	Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction.	Blood	2016	15
17018625	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	Cai W	In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3.	Cancer research	2006	70
17875985	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	Bartlett DW	Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging.	Proceedings of the National Academy of Sciences of the United States of America	2007	208
17942800	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	Cai W	Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature.	Journal of nuclear medicine 	2007	126
21373764	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	Hong H	Positron emission tomography imaging of CD105 expression during tumor angiogenesis.	European journal of nuclear medicine and molecular imaging	2011	54
15380745	arginyl-glycyl-aspartic acid	Chen X	MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides.	Molecular imaging and biology 	2004	75
15520458	arginyl-glycyl-aspartic acid	Schiffelers RM	Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle.	Nucleic acids research	2004	136
20538762	arginyl-glycyl-aspartic acid	Han HD	Targeted gene silencing using RGD-labeled chitosan nanoparticles.	Clinical cancer research 	2010	51
20660730	arginyl-glycyl-aspartic acid	Liu M	D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms.	Proceedings of the National Academy of Sciences of the United States of America	2010	47
24422585	arginyl-glycyl-aspartic acid	Kunjachan S	Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines.	Nano letters	2014	46
14983034	Angiogenesis Inhibitors	Bråkenhielm E	Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis.	Proceedings of the National Academy of Sciences of the United States of America	2004	134
17545548	Angiogenesis Inhibitors	Dings RP	Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization.	Clinical cancer research 	2007	89
17606729	Angiogenesis Inhibitors	Manning EA	A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism.	Clinical cancer research 	2007	67
18316578	Angiogenesis Inhibitors	Fernando NT	Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.	Clinical cancer research 	2008	55
19249680	Angiogenesis Inhibitors	Pàez-Ribes M	Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.	Cancer cell	2009	699
19759263	Angiogenesis Inhibitors	Olson P	MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer.	Genes & development	2009	98
19809158	Angiogenesis Inhibitors	Maione F	Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models.	The Journal of clinical investigation	2009	49
20194633	Angiogenesis Inhibitors	Helfrich I	Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma.	The Journal of experimental medicine	2010	50
20631075	Angiogenesis Inhibitors	Shrimali RK	Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.	Cancer research	2010	118
21436589	Angiogenesis Inhibitors	Cascone T	Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.	The Journal of clinical investigation	2011	45
23045683	Angiogenesis Inhibitors	Huang Y	Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.	Proceedings of the National Academy of Sciences of the United States of America	2012	133
25117977	Angiogenesis Inhibitors	Baker GJ	Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.	Neoplasia	2014	30
25892230	Angiogenesis Inhibitors	Rivera LB	Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.	Cell reports	2015	32
26908627	Angiogenesis Inhibitors	Bid HK	The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma.	Molecular cancer therapeutics	2016	11
8290962	SERPIN-B5	Zou Z	Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells.	Science	1994	183
10655109	SERPIN-B5	Zhang M	Maspin is an angiogenesis inhibitor.	Nature medicine	2000	98
17377533	SERPIN-B5	Luo JL	Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin.	Nature	2007	139
23770133	SERPIN-B5	Yuan K	Decreased levels of miR-224 and the passenger strand of miR-221 increase MBD2, suppressing maspin and promoting colorectal tumor growth and metastasis in mice.	Gastroenterology	2013	30
26454217	honokiol	Yeh PS	Honokiol induces autophagy of neuroblastoma cells through activating the PI3K/Akt/mTOR and endoplasmic reticular stress/ERK1/2 signaling pathways and suppressing cell migration.	Cancer letters	2016	14
15549107	8-(3-chlorostyryl)caffeine	Singh SK	Identification of human brain tumour initiating cells.	Nature	2004	1948
17483311	8-(3-chlorostyryl)caffeine	Beier D	CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.	Cancer research	2007	326
18559513	8-(3-chlorostyryl)caffeine	Zhang M	Identification of tumor-initiating cells in a p53-null mouse model of breast cancer.	Cancer research	2008	119
19351838	8-(3-chlorostyryl)caffeine	Wakimoto H	Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.	Cancer research	2009	124
20028757	8-(3-chlorostyryl)caffeine	Charafe-Jauffret E	Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer.	Clinical cancer research 	2010	238
20832727	8-(3-chlorostyryl)caffeine	Iliopoulos D	Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells.	Molecular cell	2010	136
21098716	8-(3-chlorostyryl)caffeine	Krishnamurthy S	Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells.	Cancer research	2010	78
21224357	8-(3-chlorostyryl)caffeine	Liu S	Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks.	Cancer research	2011	167
21498635	8-(3-chlorostyryl)caffeine	Silva IA	Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.	Cancer research	2011	133
22096026	8-(3-chlorostyryl)caffeine	Cioffi M	EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells.	Clinical cancer research 	2012	30
18641653	Poly I-C	Pobezinskaya YL	The function of TRADD in signaling through tumor necrosis factor receptor 1 and TRIF-dependent Toll-like receptors.	Nature immunology	2008	52
22308357	Poly I-C	Shime H	Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors.	Proceedings of the National Academy of Sciences of the United States of America	2012	50
24043898	Poly I-C	Rayamajhi M	Cutting edge: Mouse NAIP1 detects the type III secretion system needle protein.	Journal of immunology	2013	50
24720881	Poly I-C	Pradhan P	The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma.	Biomaterials	2014	25
25015821	Poly I-C	Polykratis A	Cutting edge: RIPK1 Kinase inactive mice are viable and protected from TNF-induced necroptosis in vivo.	Journal of immunology	2014	53
1549603	sulforafan	Zhang Y	A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure.	Proceedings of the National Academy of Sciences of the United States of America	1992	251
12032331	sulforafan	Fahey JW	Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzoapyrene-induced stomach tumors.	Proceedings of the National Academy of Sciences of the United States of America	2002	139
12234984	sulforafan	Thimmulappa RK	Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray.	Cancer research	2002	285
14514658	sulforafan	Singh AV	Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo.	Carcinogenesis	2004	94
15764812	sulforafan	Singh SV	Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species.	The Journal of biological chemistry	2005	94
16407454	sulforafan	Myzak MC	Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice.	FASEB journal 	2006	98
16516379	sulforafan	Hu R	Gene expression profiles induced by cancer chemopreventive isothiocyanate sulforaphane in the liver of C57BL/6J mice and C57BL/6J/Nrf2 (-/-) mice.	Cancer letters	2006	70
16912211	sulforafan	Xu C	Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2.	Cancer research	2006	112
16951197	sulforafan	Keum YS	Mechanism of action of sulforaphane: inhibition of p38 mitogen-activated protein kinase isoforms contributing to the induction of antioxidant response element-mediated heme oxygenase-1 in human hepatoma HepG2 cells.	Cancer research	2006	62
17259330	sulforafan	Myzak MC	Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects.	Experimental biology and medicine	2007	101
17555985	sulforafan	Dashwood RH	Dietary histone deacetylase inhibitors: from cells to mice to man.	Seminars in cancer biology	2007	90
18829980	sulforafan	Kallifatidis G	Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling.	Gut	2009	62
19223537	sulforafan	Singh SV	Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells.	Cancer research	2009	65
20388854	sulforafan	Li Y	Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells.	Clinical cancer research 	2010	126
20439747	sulforafan	Ahn YH	Electrophilic tuning of the chemoprotective natural product sulforaphane.	Proceedings of the National Academy of Sciences of the United States of America	2010	43
20530687	sulforafan	Rausch V	Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics.	Cancer research	2010	46
20940707	sulforafan	Kallifatidis G	Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate.	Molecular therapy 	2011	45
23129257	sulforafan	Li SH	Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway.	Molecular and cellular biochemistry	2013	30
23416117	sulforafan	Zhang C	Sulforaphane enhances Nrf2 expression in prostate cancer TRAMP C1 cells through epigenetic regulation.	Biochemical pharmacology	2013	37
24441674	sulforafan	Su ZY	Requirement and epigenetics reprogramming of Nrf2 in suppression of tumor promoter TPA-induced mouse skin cell transformation by sulforaphane.	Cancer prevention research	2014	31
24637114	sulforafan	Pekovic-Vaughan V	The circadian clock regulates rhythmic activation of the NRF2/glutathione-mediated antioxidant defense pathway to modulate pulmonary fibrosis.	Genes & development	2014	44
24948812	sulforafan	Wang X	Nrf2 upregulates ATP binding cassette transporter expression and activity at the blood-brain and blood-spinal cord barriers.	The Journal of neuroscience 	2014	29
25159108	sulforafan	Yager JD	Mechanisms of estrogen carcinogenesis: The role of E2/E1-quinone metabolites suggests new approaches to preventive intervention--A review.	Steroids	2015	22
11016644	vorinostat	Butler LM	Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.	Cancer research	2000	143
15596714	vorinostat	Shao Y	Apoptotic and autophagic cell death induced by histone deacetylase inhibitors.	Proceedings of the National Academy of Sciences of the United States of America	2004	169
17325656	vorinostat	Lin HS	Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents.	British journal of pharmacology	2007	58
18413790	vorinostat	Fournel M	MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.	Molecular cancer therapeutics	2008	75
18568076	vorinostat	Reddy P	Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice.	The Journal of clinical investigation	2008	98
19789319	vorinostat	Palmieri D	Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks.	Clinical cancer research 	2009	47
20647567	vorinostat	Bachmann PS	Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.	Blood	2010	44
22140466	vorinostat	Mielcarek M	SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease.	PloS one	2011	49
24396039	vorinostat	Xie M	Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy.	Circulation	2014	68
24603818	vorinostat	Sanders YY	Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice.	The European respiratory journal	2014	24
15343380	zoledronic acid	Giraudo E	An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis.	The Journal of clinical investigation	2004	167
18695136	zoledronic acid	Ottewell PD	Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.	Journal of the National Cancer Institute	2008	54
19818098	zoledronic acid	Coscia M	Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway.	Journal of cellular and molecular medicine	2010	68
20570927	zoledronic acid	Zhang W	Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.	Clinical cancer research 	2010	92
22215137	zoledronic acid	Porembka MR	Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth.	Cancer immunology, immunotherapy 	2012	61
25595279	zoledronic acid	Gonzalez-Villasana V	Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer.	Clinical cancer research 	2015	19
15087398	JM 3100	Tavor S	CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.	Cancer research	2004	78
15574767	JM 3100	Smith MC	CXCR4 regulates growth of both primary and metastatic breast cancer.	Cancer research	2004	213
16489019	JM 3100	Yasumoto K	Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer.	Cancer research	2006	62
17893878	JM 3100	Kajiyama H	Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma.	International journal of cancer	2008	79
19050309	JM 3100	Nervi B	Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.	Blood	2009	148
19588204	JM 3100	Matsusue R	Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis.	Annals of surgical oncology	2009	45
20179352	JM 3100	Kioi M	Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.	The Journal of clinical investigation	2010	207
21618540	JM 3100	Ping YF	The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling.	The Journal of pathology	2011	52
21742774	JM 3100	Righi E	CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer.	Cancer research	2011	51
22871210	JM 3100	Zhang SS	CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients.	BMC medicine	2012	46
23630186	JM 3100	Gassenmaier M	CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis.	Stem cells	2013	27
24277834	JM 3100	Feig C	Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.	Proceedings of the National Academy of Sciences of the United States of America	2013	169
25444927	JM 3100	Guan G	The HIF-1α/CXCR4 pathway supports hypoxia-induced metastasis of human osteosarcoma cells.	Cancer letters	2015	16
26031918	JM 3100	Cho BS	Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy.	Blood	2015	20
26996301	JM 3100	Wang HH	Mesenchymal stem cells generate pericytes to promote tumor recurrence via vasculogenesis after stereotactic body radiation therapy.	Cancer letters	2016	12
27481956	JM 3100	Hatzistergos KE	Stimulatory Effects of Mesenchymal Stem Cells on cKit+ Cardiac Stem Cells Are Mediated by SDF1/CXCR4 and SCF/cKit Signaling Pathways.	Circulation research	2016	13
11238559	sodium sulfate	Bertolotti A	Increased sensitivity to dextran sodium sulfate colitis in IRE1beta-deficient mice.	The Journal of clinical investigation	2001	118
21118981	sodium sulfate	Hu B	Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4.	Proceedings of the National Academy of Sciences of the United States of America	2010	101
21490396	sodium sulfate	Lerner I	Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice.	The Journal of clinical investigation	2011	43
22354874	sodium sulfate	Hyun YS	Role of IL-17A in the development of colitis-associated cancer.	Carcinogenesis	2012	40
23766441	sodium sulfate	Pope JL	Claudin-1 regulates intestinal epithelial homeostasis through the modulation of Notch-signalling.	Gut	2014	23
23793223	sodium sulfate	Bersudsky M	Non-redundant properties of IL-1α and IL-1β during acute colon inflammation in mice.	Gut	2014	39
24025712	sodium sulfate	Torres S	Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer.	Clinical cancer research 	2013	45
24487592	sodium sulfate	Westphalen CB	Long-lived intestinal tuft cells serve as colon cancer-initiating cells.	The Journal of clinical investigation	2014	84
24686242	sodium sulfate	Blat D	Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells.	Molecular therapy 	2014	26
24931456	sodium sulfate	Liu S	A microRNA 221- and 222-mediated feedback loop maintains constitutive activation of NFκB and STAT3 in colorectal cancer cells.	Gastroenterology	2014	31
25915426	sodium sulfate	Yang YR	Elevated O-GlcNAcylation promotes colonic inflammation and tumorigenesis by modulating NF-κB signaling.	Oncotarget	2015	18
26107252	sodium sulfate	Wilson JE	Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt.	Nature medicine	2015	40
27864128	sodium sulfate	Kim HB	Prostaglandin E2 Activates YAP and a Positive-Signaling Loop to Promote Colon Regeneration After Colitis but Also Carcinogenesis in Mice.	Gastroenterology	2017	9
8710878	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Baumann H	The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors.	Proceedings of the National Academy of Sciences of the United States of America	1996	136
16041381	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Jenkins BJ	Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling.	Nature medicine	2005	75
19185844	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Bollrath J	gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis.	Cancer cell	2009	256
20042582	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Matsumoto S	Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model.	Journal of immunology	2010	54
20530204	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Sander LE	Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function.	The Journal of experimental medicine	2010	93
20713517	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Inda MM	Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.	Genes & development	2010	172
20953899	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Seike T	Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis.	Clinical & experimental metastasis	2011	38
21145125	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Chalaris A	The soluble Interleukin 6 receptor: generation and role in inflammation and cancer.	European journal of cell biology	2011	51
21586612	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Corcoran RB	STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis.	Cancer research	2011	113
21926464	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Fisher DT	IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells.	The Journal of clinical investigation	2011	54
22891351	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Couto JP	STAT3 negatively regulates thyroid tumorigenesis.	Proceedings of the National Academy of Sciences of the United States of America	2012	43
23153532	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Calon A	Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation.	Cancer cell	2012	157
23345334	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Wang Z	Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis.	Journal of immunology	2013	38
23948300	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Putoczki TL	Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically.	Cancer cell	2013	63
24804649	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Judd LM	Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo.	PloS one	2014	20
25731159	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Taniguchi K	A gp130-Src-YAP module links inflammation to epithelial regeneration.	Nature	2015	84
27096320	2-phenyl-5,5-dimethyltetrahydro-1,4-oxazine	Zhang C	CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer.	Immunity	2016	13
12006510	tanespimycin	Solit DB	17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.	Clinical cancer research 	2002	96
21478269	tanespimycin	Li D	Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells.	Molecular cancer research 	2011	68
21907929	tanespimycin	De Raedt T	Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.	Cancer cell	2011	80
22439642	tanespimycin	Vinci M	Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation.	BMC biology	2012	138
22806877	tanespimycin	Shimamura T	Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.	Clinical cancer research 	2012	42
14744855	lysophosphatidic acid	Hama K	Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1.	The Journal of biological chemistry	2004	76
15599396	lysophosphatidic acid	Boucharaba A	Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer.	The Journal of clinical investigation	2004	103
16782887	lysophosphatidic acid	van Meeteren LA	Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development.	Molecular and cellular biology	2006	155
16829511	lysophosphatidic acid	Tanaka M	Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid.	The Journal of biological chemistry	2006	129
18544649	lysophosphatidic acid	Guillermet-Guibert J	The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma.	Proceedings of the National Academy of Sciences of the United States of America	2008	128
19001604	lysophosphatidic acid	Yu S	Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells.	Journal of the National Cancer Institute	2008	62
19477432	lysophosphatidic acid	Liu S	Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases.	Cancer cell	2009	128
20360563	lysophosphatidic acid	Albers HM	Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation.	Proceedings of the National Academy of Sciences of the United States of America	2010	65
21041624	lysophosphatidic acid	Su F	Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer.	Proceedings of the National Academy of Sciences of the United States of America	2010	56
22884261	lysophosphatidic acid	Miller E	Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP.	Chemistry & biology	2012	85
25024203	lysophosphatidic acid	Xiong S	Pla2g16 phospholipase mediates gain-of-function activities of mutant p53.	Proceedings of the National Academy of Sciences of the United States of America	2014	24
26109050	lysophosphatidic acid	Moroishi T	A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis.	Genes & development	2015	56
27981605	lysophosphatidic acid	Kaffe E	Hepatocyte autotaxin expression promotes liver fibrosis and cancer.	Hepatology	2017	8
17638899	CY5.5 cyanine dye	Veiseh M	Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci.	Cancer research	2007	115
20403397	CY5.5 cyanine dye	Kim K	Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring.	Journal of controlled release 	2010	49
11504908	temsirolimus	Neshat MS	Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.	Proceedings of the National Academy of Sciences of the United States of America	2001	217
16341243	temsirolimus	Thomas GV	Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.	Nature medicine	2006	169
17409454	temsirolimus	Petricoin EF 3rd	Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival.	Cancer research	2007	71
20068177	temsirolimus	Yu K	Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.	Cancer research	2010	58
21285988	temsirolimus	Wang Y	Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines.	British journal of cancer	2011	38
22378068	temsirolimus	Shi WY	Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.	Cell death & disease	2012	56
26463117	temsirolimus	Arriola Apelo SI	Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system.	Aging cell	2016	21
20819928	8-phenyl-2-(di-n-propylamino)tetralin	Joncker NT	Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment.	The Journal of experimental medicine	2010	86
21233417	8-phenyl-2-(di-n-propylamino)tetralin	Kim HJ	CD8+ T regulatory cells express the Ly49 Class I MHC receptor and are defective in autoimmune prone B6-Yaa mice.	Proceedings of the National Academy of Sciences of the United States of America	2011	52
22261438	8-phenyl-2-(di-n-propylamino)tetralin	Gordon SM	The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation.	Immunity	2012	158
16237046	CPG-oligonucleotide	Mellor AL	Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling.	Journal of immunology	2005	97
21039467	CPG-oligonucleotide	Buhtoiarov IN	Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.	Immunology	2011	40
24480625	CPG-oligonucleotide	Ali OA	Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants.	Cancer research	2014	23
11350918	gefitinib	Ciardiello F	Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.	Clinical cancer research 	2001	85
11751413	gefitinib	Moulder SL	Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.	Cancer research	2001	99
12384534	gefitinib	Wakeling AE	ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.	Cancer research	2002	135
15199112	gefitinib	Shou J	Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.	Journal of the National Cancer Institute	2004	288
15289342	gefitinib	Huang S	Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.	Cancer research	2004	74
15922853	gefitinib	Christensen JG	c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.	Cancer letters	2005	120
16648858	gefitinib	Ferby I	Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation.	Nature medicine	2006	95
16672372	gefitinib	Ji H	Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.	Proceedings of the National Academy of Sciences of the United States of America	2006	73
16705038	gefitinib	Politi K	Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.	Genes & development	2006	130
17470737	gefitinib	Arpino G	Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.	Journal of the National Cancer Institute	2007	62
17699871	gefitinib	Ritter CA	Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.	Clinical cancer research 	2007	172
18568074	gefitinib	Guix M	Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.	The Journal of clinical investigation	2008	177
18632637	gefitinib	Shimamura T	Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.	Cancer research	2008	57
19843665	gefitinib	Wang W	Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.	Clinical cancer research 	2009	69
20215504	gefitinib	Schoeberl B	An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.	Cancer research	2010	94
21037017	gefitinib	Chang TH	Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.	American journal of respiratory and critical care medicine	2011	41
22057914	gefitinib	Cheng Y	MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis.	Molecular cancer therapeutics	2012	40
22105169	gefitinib	Fukuoka H	EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.	The Journal of clinical investigation	2011	37
22317763	gefitinib	Wang W	Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.	Clinical cancer research 	2012	32
22414764	gefitinib	Blivet-Van Eggelpoël MJ	Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.	Journal of hepatology	2012	39
22844075	gefitinib	Nakagawa T	Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.	Molecular cancer therapeutics	2012	31
23307622	gefitinib	Cufí S	Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.	Oncotarget	2012	33
23461856	gefitinib	Ma L	Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma.	The FEBS journal	2013	26
24165158	gefitinib	Rho JK	MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.	Cancer research	2014	30
24535670	gefitinib	de Bruin EC	Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.	Cancer discovery	2014	42
24911146	gefitinib	Park KS	CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.	The Journal of clinical investigation	2014	20
24939055	gefitinib	Qu Y	Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.	Journal of experimental & clinical cancer research 	2014	24
24983493	gefitinib	Zhou JY	MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.	Cancer letters	2014	21
25925741	gefitinib	Dong S	The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.	Journal of hematology & oncology	2015	26
26282169	gefitinib	Soucheray M	Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.	Cancer research	2015	19
27251290	gefitinib	Jia Y	Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.	Nature	2016	47
28271729	gefitinib	Ahn MJ	EGFR TKI combination with immunotherapy in non-small cell lung cancer.	Expert opinion on drug safety	2017	10
12183421	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Wedge SR	ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.	Cancer research	2002	163
12499271	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Carlomagno F	ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.	Cancer research	2002	115
14760102	N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	Ciardiello F	Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.	Clinical cancer research 	2004	77
10197582	BH 3	Korsmeyer SJ	BCL-2 gene family and the regulation of programmed cell death.	Cancer research	1999	123
12876200	BH 3	Ranger AM	Bad-deficient mice develop diffuse large B cell lymphoma.	Proceedings of the National Academy of Sciences of the United States of America	2003	78
14500851	BH 3	Villunger A	p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa.	Science	2003	405
16122425	BH 3	Zinkel SS	A role for proapoptotic BID in the DNA-damage response.	Cell	2005	76
17360431	BH 3	Schmelzle T	Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2007	66
17671092	BH 3	George NM	A three-helix homo-oligomerization domain containing BH3 and BH1 is responsible for the apoptotic activity of Bax.	Genes & development	2007	63
17927446	BH 3	Gong Y	Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas.	PLoS medicine	2007	118
18949058	BH 3	Cragg MS	Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.	The Journal of clinical investigation	2008	72
20935509	BH 3	Kang R	HMGB1: a novel Beclin 1-binding protein active in autophagy.	Autophagy	2010	44
21911424	BH 3	Josefsson EC	Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets.	The Journal of experimental medicine	2011	42
23332762	BH 3	Yan J	Inactivation of BAD by IKK inhibits TNFα-induced apoptosis independently of NF-κB activation.	Cell	2013	27
23532334	BH 3	Bean GR	PUMA and BIM are required for oncogene inactivation-induced apoptosis.	Science signaling	2013	36
23680104	BH 3	Cao X	The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak.	Molecular cancer	2013	25
24019208	BH 3	Abulwerdi F	A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo.	Molecular cancer therapeutics	2014	49
24488097	BH 3	Fiori ME	Antitumor effect of miR-197 targeting in p53 wild-type lung cancer.	Cell death and differentiation	2014	24
25493329	BH 3	Pérez-Hernández M	Dissecting the molecular mechanism of apoptosis during photothermal therapy using gold nanoprisms.	ACS nano	2015	20
25715028	BH 3	Pedro JM	BAX and BAK1 are dispensable for ABT-737-induced dissociation of the BCL2-BECN1 complex and autophagy.	Autophagy	2015	22
25952548	BH 3	Delbridge AR	The BCL-2 protein family, BH3-mimetics and cancer therapy.	Cell death and differentiation	2015	69
28017613	BH 3	Sarosiek KA	Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics.	Cancer cell	2017	15
12543936	alpha-galactosylceramide	Taniguchi M	The regulatory role of Valpha14 NKT cells in innate and acquired immune response.	Annual review of immunology	2003	188
16116198	alpha-galactosylceramide	Uldrich AP	NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge.	Journal of immunology	2005	72
16275765	alpha-galactosylceramide	Crowe NY	Differential antitumor immunity mediated by NKT cell subsets in vivo.	The Journal of experimental medicine	2005	122
17372206	alpha-galactosylceramide	Porubsky S	Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency.	Proceedings of the National Academy of Sciences of the United States of America	2007	79
19234176	alpha-galactosylceramide	Parekh VV	PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells.	Journal of immunology	2009	69
16452222	lapatinib	Konecny GE	Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.	Cancer research	2006	223
18664652	lapatinib	Gril B	Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.	Journal of the National Cancer Institute	2008	78
19056914	lapatinib	Polli JW	An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-(3-fluorobenzyl)oxyphenyl}-6-5-({2-(methylsulfonyl)ethylamino}methyl)-2-furyl-4-quinazolinamine; GW572016).	Drug metabolism and disposition	2009	66
19934303	lapatinib	Miller TW	Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells.	Clinical cancer research 	2009	53
21510863	lapatinib	Barok M	Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.	Breast cancer research 	2011	44
22011930	lapatinib	Taskar KS	Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.	Pharmaceutical research	2012	46
22461506	lapatinib	Vaught DB	HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation.	Cancer research	2012	38
23441129	lapatinib	Walters DM	Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.	Neoplasia	2013	28
23918797	lapatinib	Garrett JT	Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.	Cancer research	2013	33
23940356	lapatinib	Hanker AB	Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.	Proceedings of the National Academy of Sciences of the United States of America	2013	43
23943608	lapatinib	Kirouac DC	Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.	Science signaling	2013	32
24097864	lapatinib	Phillips GD	Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.	Clinical cancer research 	2014	36
24451154	lapatinib	Rexer BN	Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.	Breast cancer research 	2014	23
26337386	lapatinib	Lin CH	Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors.	Molecular biology of the cell	2015	19
16507829	sorafenib	Carlomagno F	BAY 43-9006 inhibition of oncogenic RET mutants.	Journal of the National Cancer Institute	2006	94
17160391	sorafenib	Chang YS	Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.	Cancer chemotherapy and pharmacology	2007	108
18230792	sorafenib	Zhang W	Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.	Journal of the National Cancer Institute	2008	109
18310500	sorafenib	Hipp MM	Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses.	Blood	2008	71
19726678	sorafenib	Bai S	MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib.	The Journal of biological chemistry	2009	157
20495567	sorafenib	Sheng Z	A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.	Nature medicine	2010	53
20616044	sorafenib	Wüstehube J	Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by activating DELTA-NOTCH signaling.	Proceedings of the National Academy of Sciences of the United States of America	2010	47
20799354	sorafenib	Hikita H	The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.	Hepatology	2010	50
20884624	sorafenib	Chen KF	Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3.	Clinical cancer research 	2010	50
20952483	sorafenib	Agarwal S	The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.	The Journal of pharmacology and experimental therapeutics	2011	51
21354226	sorafenib	Tai WT	Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.	Journal of hepatology	2011	46
21368833	sorafenib	Inuzuka H	SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction.	Nature	2011	195
21858812	sorafenib	Shimizu S	Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.	International journal of cancer	2012	56
22318717	sorafenib	Ma WL	Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis.	Hepatology	2012	35
22368270	sorafenib	Man CH	Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.	Blood	2012	62
22446485	sorafenib	Rahmani M	Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.	Blood	2012	36
22811581	sorafenib	Lachenmayer A	Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.	Clinical cancer research 	2012	56
22958930	sorafenib	Chu SH	FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm.	Cell stem cell	2012	40
23257894	sorafenib	Shen YC	Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma.	British journal of cancer	2013	30
23299930	sorafenib	Liang Y	Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.	Hepatology	2013	53
23434734	sorafenib	Pignochino Y	The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.	Clinical cancer research 	2013	26
23796475	sorafenib	Kapanadze T	Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.	Journal of hepatology	2013	33
24046014	sorafenib	Zimmerman EI	Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.	Blood	2013	43
24242874	sorafenib	Chen Y	Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.	Hepatology	2014	32
24687604	sorafenib	Horwitz E	Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.	Cancer discovery	2014	21
24700742	sorafenib	Xiang Q	Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.	Clinical cancer research 	2014	26
25053293	sorafenib	Fernando J	A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells.	International journal of cancer	2015	23
25216638	sorafenib	Rudalska R	In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.	Nature medicine	2014	43
25529917	sorafenib	Chen Y	CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.	Hepatology	2015	47
25865556	sorafenib	Han T	PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients.	Journal of hepatology	2015	19
26592953	sorafenib	Govaere O	Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche.	Journal of hepatology	2016	13
26924089	sorafenib	Zhou SL	Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.	Gastroenterology	2016	22
12538485	sunitinib	Mendel DB	In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.	Clinical cancer research 	2003	393
12748309	sunitinib	Abrams TJ	SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.	Molecular cancer therapeutics	2003	147
15557593	sunitinib	Pietras K	A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.	Journal of clinical oncology 	2005	112
17942672	sunitinib	Ebos JM	Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.	Proceedings of the National Academy of Sciences of the United States of America	2007	115
19244102	sunitinib	Xin H	Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells.	Cancer research	2009	142
19249681	sunitinib	Ebos JM	Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.	Cancer cell	2009	509
19276342	sunitinib	Ozao-Choy J	The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.	Cancer research	2009	161
19887629	sunitinib	Lee SL	Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model.	Proceedings of the National Academy of Sciences of the United States of America	2009	59
20406969	sunitinib	Ko JS	Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.	Cancer research	2010	85
20501804	sunitinib	Hammers HJ	Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.	Molecular cancer therapeutics	2010	56
21170961	sunitinib	Bose A	Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination.	International journal of cancer	2011	50
21237299	sunitinib	Greten TF	Myeloid derived suppressor cells in human diseases.	International immunopharmacology	2011	112
21315783	sunitinib	Finke J	MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.	International immunopharmacology	2011	73
21633954	sunitinib	Farsaci B	Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy.	International journal of cancer	2012	42
22308314	sunitinib	Conley SJ	Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia.	Proceedings of the National Academy of Sciences of the United States of America	2012	160
22484816	sunitinib	Maione F	Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice.	The Journal of clinical investigation	2012	36
22965162	sunitinib	Piao Y	Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.	Neuro-oncology	2012	54
23108136	sunitinib	Terme M	VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.	Cancer research	2013	70
23720580	sunitinib	Chintalgattu V	Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity.	Science translational medicine	2013	28
25149532	sunitinib	Babae N	Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma.	Oncotarget	2014	26
25200065	sunitinib	Zhang D	Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer.	Molecular cancer	2014	25
25361735	sunitinib	Huang H	VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation.	FASEB journal 	2015	22
25381264	sunitinib	Ciamporcero E	Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.	Molecular cancer therapeutics	2015	19
25861727	sunitinib	Costa PM	MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma.	Journal of controlled release 	2015	22
27595394	sunitinib	Chen W	Targeting renal cell carcinoma with a HIF-2 antagonist.	Nature	2016	39
12649187	cucurbitacin I	Blaskovich MA	Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.	Cancer research	2003	171
21915101	cucurbitacin I	Zhuang X	Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain.	Molecular therapy 	2011	163
21295276	5-hydroxymethylcytosine	Koh KP	Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells.	Cell stem cell	2011	262
21722948	5-hydroxymethylcytosine	Cortellino S	Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair.	Cell	2011	276
21803851	5-hydroxymethylcytosine	Li Z	Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies.	Blood	2011	163
21873190	5-hydroxymethylcytosine	Ko M	Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice.	Proceedings of the National Academy of Sciences of the United States of America	2011	137
21940858	5-hydroxymethylcytosine	Inoue A	Replication-dependent loss of 5-hydroxymethylcytosine in mouse preimplantation embryos.	Science	2011	172
22391558	5-hydroxymethylcytosine	Yang H	Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation.	Oncogene	2013	140
22902005	5-hydroxymethylcytosine	Raiber EA	Genome-wide distribution of 5-formylcytosine in embryonic stem cells is associated with transcription and depends on thymine DNA glycosylase.	Genome biology	2012	69
23223451	5-hydroxymethylcytosine	Hackett JA	Germline DNA demethylation dynamics and imprint erasure through 5-hydroxymethylcytosine.	Science	2013	199
23353889	5-hydroxymethylcytosine	Deplus R	TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS.	The EMBO journal	2013	150
23403289	5-hydroxymethylcytosine	Hahn MA	Dynamics of 5-hydroxymethylcytosine and chromatin marks in Mammalian neurogenesis.	Cell reports	2013	132
23434322	5-hydroxymethylcytosine	Spruijt CG	Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives.	Cell	2013	272
23827711	5-hydroxymethylcytosine	Song SJ	The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation.	Cell stem cell	2013	95
23828890	5-hydroxymethylcytosine	Lister R	Global epigenomic reconfiguration during mammalian brain development.	Science	2013	449
23850245	5-hydroxymethylcytosine	Ficz G	FGF signaling inhibition in ESCs drives rapid genome-wide demethylation to the epigenetic ground state of pluripotency.	Cell stem cell	2013	107
24270360	5-hydroxymethylcytosine	Jeong M	Large conserved domains of low DNA methylation maintained by Dnmt3a.	Nature genetics	2014	88
24735881	5-hydroxymethylcytosine	Dawlaty MM	Loss of Tet enzymes compromises proper differentiation of embryonic stem cells.	Developmental cell	2014	56
25867473	5-hydroxymethylcytosine	Cimmino L	TET1 is a tumor suppressor of hematopoietic malignancy.	Nature immunology	2015	48
25915124	5-hydroxymethylcytosine	Etchegaray JP	The histone deacetylase SIRT6 controls embryonic stem cell fate via TET-mediated production of 5-hydroxymethylcytosine.	Nature cell biology	2015	34
26287468	5-hydroxymethylcytosine	Zhang Q	Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6.	Nature	2015	45
27869820	5-hydroxymethylcytosine	Tsagaratou A	TET proteins regulate the lineage specification and TCR-mediated expansion of iNKT cells.	Nature immunology	2017	8
17146434	nutlin 3	Ambrosini G	Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.	Oncogene	2007	55
17364023	nutlin 3	Sarek G	Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.	The Journal of clinical investigation	2007	56
20606252	nutlin 3	Korotchkina LG	The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway.	Aging	2010	162
23187803	nutlin 3	Leontieva OV	Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells.	Cell cycle	2012	64
25526089	nutlin 3	Li L	A unique role for p53 in the regulation of M2 macrophage polarization.	Cell death and differentiation	2015	16
25924068	nutlin 3	Drost J	Sequential cancer mutations in cultured human intestinal stem cells.	Nature	2015	100
16428510	panobinostat	Qian DZ	Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.	Clinical cancer research 	2006	75
19828702	panobinostat	Wang Y	Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.	Blood	2009	50
22367781	panobinostat	Rao R	Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.	Molecular cancer therapeutics	2012	40
22613095	panobinostat	Tate CR	Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.	Breast cancer research 	2012	55
24415537	panobinostat	Bots M	Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors.	Blood	2014	23
24435446	panobinostat	Fiskus W	Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.	Molecular cancer therapeutics	2014	43
28052119	panobinostat	Hennika T	Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models.	PloS one	2017	8
21451123	PD 0325901	Lyubynska N	A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.	Science translational medicine	2011	42
22064351	PD 0325901	Konopleva M	MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.	Leukemia	2012	45
22350410	PD 0325901	Mulholland DJ	Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells.	Cancer research	2012	134
22836754	PD 0325901	Wang J	B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer.	Cancer research	2012	31
23221337	PD 0325901	Chang T	Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.	The Journal of clinical investigation	2013	42
23221341	PD 0325901	Jessen WJ	MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.	The Journal of clinical investigation	2013	74
24315826	PD 0325901	Collins MA	MAPK signaling is required for dedifferentiation of acinar cells and development of pancreatic intraepithelial neoplasia in mice.	Gastroenterology	2014	22
24711431	PD 0325901	McFadden DG	p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.	Proceedings of the National Academy of Sciences of the United States of America	2014	32
25195567	PD 0325901	Paulo JA	Effects of MEK inhibitors GSK1120212 and PD0325901 in vivo using 10-plex quantitative proteomics and phosphoproteomics.	Proteomics	2015	23
28215705	PD 0325901	Burgess MR	KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.	Cell	2017	6
17332304	AZD 6244	Yeh TC	Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.	Clinical cancer research 	2007	172
17699718	AZD 6244	Davies BR	AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models.	Molecular cancer therapeutics	2007	141
19029981	AZD 6244	Engelman JA	Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.	Nature medicine	2008	484
21124782	AZD 6244	Meng J	Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.	PloS one	2010	57
22392911	AZD 6244	Migliardi G	Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.	Clinical cancer research 	2012	48
22872574	AZD 6244	Roberts PJ	Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.	Clinical cancer research 	2012	65
25348516	AZD 6244	Alagesan B	Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer.	Clinical cancer research 	2015	29
26677984	AZD 6244	Choi E	Expression of Activated Ras in Gastric Chief Cells of Mice Leads to the Full Spectrum of Metaplastic Lineage Transitions.	Gastroenterology	2016	17
27599525	AZD 6244	Quan-Jun Y	Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation.	Molecular cancer therapeutics	2017	6
28029918	AZD 6244	Dombi E	Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.	The New England journal of medicine	2016	24
23245996	navitoclax	Corcoran RB	Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models.	Cancer cell	2013	101
24163374	navitoclax	Faber AC	mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.	Cancer discovery	2014	42
25737542	navitoclax	Faber AC	Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.	Proceedings of the National Academy of Sciences of the United States of America	2015	28
26657143	navitoclax	Chang J	Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice.	Nature medicine	2016	109
20498063	PLX 4720	Nucera C	B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.	Proceedings of the National Academy of Sciences of the United States of America	2010	66
22038996	PLX 4720	Nicolaides TP	Targeted therapy for BRAFV600E malignant astrocytoma.	Clinical cancer research 	2011	54
23204132	PLX 4720	Liu C	BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.	Clinical cancer research 	2013	89
23454771	PLX 4720	Knight DA	Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.	The Journal of clinical investigation	2013	76
24145418	PLX 4720	Yuan P	Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.	Proceedings of the National Academy of Sciences of the United States of America	2013	60
25351955	PLX 4720	Ferrari de Andrade L	Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.	Cancer research	2014	20
25624498	PLX 4720	Perna D	BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model.	Proceedings of the National Academy of Sciences of the United States of America	2015	27
25873177	PLX 4720	Hirata E	Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling.	Cancer cell	2015	65
19584292	dactolisib	McMillin DW	Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.	Cancer research	2009	46
19789349	dactolisib	Konstantinidou G	Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.	Cancer research	2009	56
20876803	dactolisib	Chiarini F	Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.	Cancer research	2010	56
21372221	dactolisib	Santiskulvong C	Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.	Clinical cancer research 	2011	43
21966435	dactolisib	Roper J	The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.	PloS one	2011	36
22355272	dactolisib	Mukherjee B	The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses.	Neoplasia	2012	57
22539746	dactolisib	Thomas HE	mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma.	Science translational medicine	2012	32
23246963	dactolisib	Montero JC	Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.	Oncogene	2014	29
26451606	dactolisib	Sharma N	PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth.	Oncotarget	2015	40
28321130	dactolisib	Lu X	Effective combinatorial immunotherapy for castration-resistant prostate cancer.	Nature	2017	16
19360080	pevonedistat	Soucy TA	An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.	Nature	2009	464
20203261	pevonedistat	Swords RT	Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.	Blood	2010	75
20525923	pevonedistat	Milhollen MA	MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.	Blood	2010	112
23633453	pevonedistat	Nawrocki ST	Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer.	Clinical cancer research 	2013	32
24430184	pevonedistat	Li H	Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis.	The Journal of clinical investigation	2014	26
20130243	INCB018424	Quintás-Cardama A	Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.	Blood	2010	164
22955920	INCB018424	Maude SL	Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.	Blood	2012	69
25207766	INCB018424	Roberts KG	Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.	The New England journal of medicine	2014	178
25645356	INCB018424	Maude SL	Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.	Blood	2015	33
26825707	INCB018424	Das R	Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis.	Blood	2016	14
27777238	INCB018424	Tasian SK	Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.	Blood	2017	15
22256804	vemurafenib	Su F	RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.	The New England journal of medicine	2012	219
22351686	vemurafenib	Paraiso KH	The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.	Clinical cancer research 	2012	53
22454535	vemurafenib	Mittapalli RK	Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).	The Journal of pharmacology and experimental therapeutics	2012	32
22693252	vemurafenib	Koya RC	BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.	Cancer research	2012	64
23242808	vemurafenib	Girotti MR	Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.	Cancer discovery	2013	106
23249624	vemurafenib	Mittapalli RK	Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases.	The Journal of pharmacology and experimental therapeutics	2013	28
23251002	vemurafenib	Mao M	Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.	Clinical cancer research 	2013	74
23603816	vemurafenib	Jameson KL	IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors.	Nature medicine	2013	51
24652991	vemurafenib	Nelson DS	Somatic activating ARAF mutations in Langerhans cell histiocytosis.	Blood	2014	30
24871132	vemurafenib	Chung SS	Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia.	Science translational medicine	2014	20
24879157	vemurafenib	Goodall ML	Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib.	Autophagy	2014	20
25807485	vemurafenib	Obenauf AC	Therapy-induced tumour secretomes promote resistance and tumour progression.	Nature	2015	81
26073081	vemurafenib	Fedorenko IV	Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.	Oncogene	2016	14
20615965	PCI 32765	Honigberg LA	The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.	Proceedings of the National Academy of Sciences of the United States of America	2010	276
21422473	PCI 32765	Herman SE	Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.	Blood	2011	188
22180443	PCI 32765	Ponader S	The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.	Blood	2012	171
22689860	PCI 32765	Tai YT	Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.	Blood	2012	48
23619564	PCI 32765	Herman SE	Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy.	Leukemia	2013	27
24311722	PCI 32765	Woyach JA	Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).	Blood	2014	48
24812669	PCI 32765	Tang CH	Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival.	The Journal of clinical investigation	2014	37
25214559	PCI 32765	Gao W	Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.	Journal of the National Cancer Institute	2014	22
25662332	PCI 32765	Sagiv-Barfi I	Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma.	Blood	2015	18
25730880	PCI 32765	Sagiv-Barfi I	Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.	Proceedings of the National Academy of Sciences of the United States of America	2015	56
25838351	PCI 32765	Hing ZA	Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.	Blood	2015	16
26582643	PCI 32765	Chen SS	BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia.	Leukemia	2016	18
26660519	PCI 32765	Niemann CU	Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.	Clinical cancer research 	2016	19
26715645	PCI 32765	Gunderson AJ	Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.	Cancer discovery	2016	44
26880800	PCI 32765	Stiff A	Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.	Cancer research	2016	16
28199309	PCI 32765	Compagno M	Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.	Nature	2017	14
9155017	cholecystokinin C-terminal flanking peptide	Waskiewicz AJ	Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2.	The EMBO journal	1997	225
9395435	cholecystokinin C-terminal flanking peptide	Sells MA	Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells.	Current biology 	1997	206
9447975	cholecystokinin C-terminal flanking peptide	Schönwasser DC	Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes.	Molecular and cellular biology	1998	156
10710310	cholecystokinin C-terminal flanking peptide	Hirao A	DNA damage-induced activation of p53 by the checkpoint kinase Chk2.	Science	2000	285
11333986	cholecystokinin C-terminal flanking peptide	Bulavin DV	Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase.	Nature	2001	128
11533658	cholecystokinin C-terminal flanking peptide	Ryo A	Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC.	Nature cell biology	2001	132
12891359	cholecystokinin C-terminal flanking peptide	Liou YC	Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration.	Nature	2003	108
15103331	cholecystokinin C-terminal flanking peptide	Yada M	Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7.	The EMBO journal	2004	240
16554819	cholecystokinin C-terminal flanking peptide	Pastorino L	The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production.	Nature	2006	135
17000121	cholecystokinin C-terminal flanking peptide	Omori SA	Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling.	Immunity	2006	73
17101782	cholecystokinin C-terminal flanking peptide	Tan Y	Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes.	Molecular and cellular biology	2007	89
17906618	cholecystokinin C-terminal flanking peptide	Plun-Favreau H	The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1.	Nature cell biology	2007	151
19131594	cholecystokinin C-terminal flanking peptide	Wegrzyn J	Function of mitochondrial Stat3 in cellular respiration.	Science	2009	246
19609947	cholecystokinin C-terminal flanking peptide	Bai D	Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt.	International journal of cancer	2009	67
20140016	cholecystokinin C-terminal flanking peptide	Wang J	Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma.	Oncogene	2010	46
20580720	cholecystokinin C-terminal flanking peptide	Lee G	Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis.	Gastroenterology	2010	57
21368761	cholecystokinin C-terminal flanking peptide	Zhang H	Functional complementation between FADD and RIP1 in embryos and lymphocytes.	Nature	2011	154
21382551	cholecystokinin C-terminal flanking peptide	Sun Y	Phosphorylation state of Olig2 regulates proliferation of neural progenitors.	Neuron	2011	41
23306062	cholecystokinin C-terminal flanking peptide	Laine A	Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.	Cancer discovery	2013	32
17891174	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Ma S	CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.	Oncogene	2008	209
18263735	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Tang Y	Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling.	Proceedings of the National Academy of Sciences of the United States of America	2008	106
18318435	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Lai JP	Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma.	Hepatology	2008	68
19524505	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Kota J	Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model.	Cell	2009	556
20141834	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Park EJ	Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression.	Cell	2010	386
20227042	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	He G	Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation.	Cancer cell	2010	113
20371487	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Wei W	S-nitrosylation from GSNOR deficiency impairs DNA repair and promotes hepatocarcinogenesis.	Science translational medicine	2010	46
20385424	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Zender L	Cancer gene discovery in hepatocellular carcinoma.	Journal of hepatology	2010	47
20637208	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Saxena NK	Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma.	Gastroenterology	2010	45
21076472	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Xu MZ	AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma.	Oncogene	2011	55
21397858	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Sawey ET	Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.	Cancer cell	2011	81
22014574	5,11,17,23-tetra-tert-butyl-25,27-bis(hydrazidecarbonylmethoxy)-26,28-dihydroxycalix(4)arene	Kim HS	SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity.	Cancer cell	2011	128
10541552	Amy1 protein, mouse	Eischen CM	Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.	Genes & development	1999	279
10541554	Amy1 protein, mouse	Jacobs JJ	Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF.	Genes & development	1999	175
10557294	Amy1 protein, mouse	Iritani BM	c-Myc enhances protein synthesis and cell size during B lymphocyte development.	Proceedings of the National Academy of Sciences of the United States of America	1999	109
16878133	Amy1 protein, mouse	Dews M	Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster.	Nature genetics	2006	347
17728759	Amy1 protein, mouse	Gorrini C	Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response.	Nature	2007	105
19686682	Amy1 protein, mouse	Zhao X	The N-Myc-DLL3 cascade is suppressed by the ubiquitin ligase Huwe1 to inhibit proliferation and promote neurogenesis in the developing brain.	Developmental cell	2009	63
22120667	Amy1 protein, mouse	Murga M	Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors.	Nature structural & molecular biology	2011	107
22195962	Amy1 protein, mouse	Hitosugi T	Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism.	Molecular cell	2011	72
